President's Report 2008

Page 2 1:43 PM 4/15/09 CoverF

ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES PRESIDENT’S REPORT 2008

Education with a global perspective

CoverF

4/15/09

1:43 PM

Page 3

MANAGING EDITOR

Christine Shields EDITOR

Gil Chorbajian CONTRIBUTING WRITERS

Gil Chorbajian James J. Gozzo Mark McCarty Christine Shields Winifred Yu CONTRIBUTING PHOTOGRAPHERS

Gil Chorbajian Don Elliott Patrick Rathbun Kris Qua Christine Shields DESIGN

Coppola Design

PrezRepVF

4/15/09

1:35 PM

Page 1

ACPHS 2008

To be truly educated, students should have a global perspective.

P R E S I D E N T ’ S M E S S A G E 2 // FA C U LT Y H I G H L I G H T S 4 // S T U D E N T H I G H L I G H T S 2 0 // F I N A N C I A L S 2 6 // S C H O L A R LY A C T I V I T Y 2 8

// 1

PrezRepVF

4/15/09

1:35 PM

Page 2

In last year’s report, I wrote, “We enjoy a strong reputation as a pharmacy college, but we aspire to something even greater — to be viewed as a truly extraordinary institute of higher learning.”

As you will read in the following pages, the College made measurable strides towards that goal in 2008. The research taking place across all departments at ACPHS is advancing health care by helping address several of the world’s most pressing health threats.

PrezRepVF

4/15/09

1:35 PM

Page 3

ACPHS 2008

// 3

P R E S I D E N T ’ S M E S SAG E

Susan Ludeman, Ph.D., for example, has an

Given the quality of the research taking place

in pharmaceutical sciences program, who

active grant from the National Cancer Institute

at ACPHS and the global importance of those

received a prestigious “Gateway to Research”

which is examining how genetic factors influ-

subjects being studied, it is little surprise that

scholarship from the American Foundation

ence the efficacy of chemotherapeutic drugs.

investigators from around the world are seeking

for Pharmacy Education to study hypoten-

to collaborate with our institution. The College

sion with his mentor, Dr. Feleder. Several

is working with academic, pharmaceutical and

more examples of exemplary student research can be found in this Report.

Thomas Lodise, Pharm.D., has received four separate grants to determine the best courses

biotechnology institutes in nearly 20 countries,

of treatment for patients infected with MRSA, a

including: Australia, China, Japan, Egypt, Saudi

potentially deadly bacteria that has been

Arabia, Turkey, Switzerland, Germany,

When one considers the impact of these and

described by NIH as ’a serious public health

Argentina, Brazil and Australia.

other initiatives, it becomes clear how our research programs are distinguishing the

concern.’

One of the primary beneficiaries of the research

College in the region, across the nation and

The College’s Pharmaceutical Research

taking place here is our students. Regardless of

around the world. As importantly, these pro-

Institute, headed by Shaker Mousa, Ph.D.,

their academic focus, students at ACPHS are

grams are providing our students with a

marked its fifth anniversary in 2008 by securing

encouraged to participate in research projects.

wider range of educational opportunities —

the largest single grant in its history. PRI will

The opportunity to work closely with faculty

from laboratory research to patient care. The

receive $1.37 million over five years to help

and contribute in a meaningful way to their

result is graduates who have a better under-

develop an antidote for anthrax as part of a

research is one not often afforded to undergrad-

standing of the full spectrum of health care

joint effort with three other institutions.

uates, and more students at the College are tak-

and a global perspective on how best to

ing advantage of these unique opportunities.

apply their knowledge.

Carlos Feleder, M.D., Ph.D., received an NIHfunded grant in 2008 to study the role of the

Jaclyn Hosmer is one such student. She is a

spleen in managing fever. On the other end of

third year Pharm.D. student who is working

the temperature spectrum, Alex Steiner,

with Assistant Professor Luciana Lopes,

Pharm.D., Ph.D., is working to understand how

Pharm.D., Ph.D., in researching new treat-

hypothermia may play a key part in preserving

ments for skin cancer. There is also Alex

tissue in patients with severe sepsis.

Villanueva, a fourth year student in the B.S.

James J. Gozzo, Ph.D.

PrezRepVF

4/15/09

1:35 PM

Page 4

Body temperature influences every chemical reaction in our bodies. In separate research projects, Dr. Carlos Feleder and Dr. Alex Steiner are taking an alternative look at the role of temperature in fighting infection.

Running hot and cold Investigating temperature’s role in fighting infection

Department of Pharmaceutical Sciences assistant professors Carlos Feleder, M.D., Ph.D, and Alex Steiner, Pharm.D., Ph.D. are looking at temperature in a new light in two separate research projects at ACPHS. Both are taking an alternative look at the role of temperature in fighting infection. Dr. Feleder recently won a grant to study the role of the spleen in fever, while Dr. Steiner is studying hypothermia’s effect on sepsis.

Though many studies have been conducted on the liver’s impact on fever, the spleen’s role remains relatively unknown. Dr. Feleder hopes to change that with a $231,000 research grant from the National Institutes of Health (NIH).

According to his research, the spleen plays an important role in managing fever by releasing a chemical that caps fever, preventing body temperature from reaching dangerous levels. The goal of his grant is to identify the chemical or ’factor’ being produced by the spleen during fever and study its mechanism of action.

“Most research in this area has focused on the liver as the key to managing fever,” says Dr. Feleder. “Our initial findings show that the activity of cells in the liver during fever is, in fact, influenced by chemicals produced in the spleen. If we understand how the body sets upper limits on temperature and learn to influence this process, we can allow the body to enjoy the benefits of fever and minimize the potential threats, thereby accelerating the recovery process.”

In the 1970s and 1980s, a University of Michigan Medical School researcher named Matthew Kluger challenged long held beliefs about fever.

Medicine’s approach to fever was to lower body temperature in the majority of cases.

However, by infecting desert lizards with bacterium, he proved fever could be beneficial. In a terrarium with hot and cold temperatures, he

gave the animals the option of voluntarily raising their body temperatures and found that those who chose to raise their temperatures survived. Fever plays a critical role in fighting infection because immune cells are more effective in killing invading bacteria at higher temperatures.

Similar to Kluger’s view of fever, Dr. Steiner sees potential in the power of hypothermia. During severe infection (systemic inflammation or sepsis), 90 percent of patients develop fever, and 10 percent develop hypothermia. Clinicians think of hypothermia as a “wrong” reaction and, much of the time, their approach is to raise body temperature. With severe sepsis the leading cause of death among patients in non-coronary intensive care units, hypothermia might actually save tissues by lowering metabolic demands and increasing profusion, Dr. Steiner says. Fever, during severe infection, can damage tissues, and hypothermia could possibly be the body’s “strategy of last resort.”

“Body temperature influences everything, every chemical reaction in your body,” Dr. Steiner explains. “We’re not talking about cooling patients; we’re talking about not heating septic patients who spontaneously become hypothermic. Inaction might be best.”

While doing postdoctoral research in Arizona, Dr. Steiner noted that rats with severe sepsis choose to stay in a cool environment where they can develop hypothermia, an indication that hypothermia might be a natural physiological response. Recognizing a gap in hypothermia research, he decided to pursue it. His research at ACPHS thus far indicates that septic rats allowed to develop hypothermia (by being kept in a cool environment) suffer less tissue injury than rats forced to develop fever (by being kept in a warm environment). He is now carrying out experiments to identify which temperature-dependent processes are primarily responsible for such protection. During fever and hypothermia, Dr. Steiner measures tissue energy in the liver and kidney for signs of injury.

Both Dr. Feleder and Dr. Steiner see room for collaboration in the future, and they say often talk to each other about their research. They can hardly avoid this, as their offices are next to each other in the Biosciences Research Building at ACPHS. Aside from temperature, they have something else in common—another of Dr. Feleder’s research projects focuses on the brain’s response to sepsis.

Dr. Alex Steiner, with research assistant Cathy Krall, measures tissue energy in the liver and kidney during fever and hypothermia.

PrezRepVF

4/15/09

1:35 PM

Page 5

ACPHS 2008

Dr. Carlos Feleder is investigating the role of the spleen in managing fever.

// 5

PrezRepVF

4/15/09

1:35 PM

Page 6

The Right Chemistry Cutting Edge Research Crosses Disciplines

Susan Ludeman, an associate professor of organic chemistry in the Department of Arts and Sciences, is working across disciplines to delve into the mechanisms of diseases such as cancer and Alzheimer’s and develop novel approaches to their treatment.

A large part of Dr. Ludeman’s current research relates to cancer. Before landing at ACPHS, she held positions as an associate professor in the Division of Medical Oncology, Department of Medicine, at Duke University Medical Center and assistant professor in the Division of Experimental Therapeutics and Pharmacology, Department of Oncology, at the Johns Hopkins University Medical Institutions. Her opportunities through these institutions have led to some exciting research collaborations; she currently has two active grants totaling $434,296.

One, through the National Cancer Institute, involves the chemistry and pharmacology of cyclophosphamide and related alkylating agents, anticancer drugs which act by modifying DNA. Many chemotherapeutics target DNA in cancer cells so as to disrupt cell function and cause cell death, explains Dr. Ludeman. But the body’s natural defense mechanisms include repair “machinery” that will attempt to fix the damage to DNA. “If we can pinpoint this repair sequence, we may be able to stop it,” Dr. Ludeman says, thus increasing the efficacy of chemotherapy.

The study also includes a pharmacogenetic component. Cyclophosphamide and related alkylating agents must be activated in the liver to be effective, but, depending on hepatic enzyme activity, these drugs are subject to competing reactions. The alternative pathways lead to toxic side effects that can significantly decrease the drugs’ effectiveness.

“A genetic factor may predetermine if the drugs will work,” says Dr. Ludeman. “With most chemotherapy, weeks or months are required before you see the effects.” By knowing ahead of time if a drug has a chance of being effective, oncologists might be able to avoid wasting precious treatment time as well as undesirable side effects.

Another grant, from the National Institute on Aging, in collaboration with North Carolina State University, involves antioxidant metabolism in the brain. Research suggests that the loss of antioxidants, especially glutathione, may speed the aging process and the onset of diseases such as Parkinson’s and Alzheimer’s.

Although scientists have tried to increase levels of glutathione to slow the effects of aging, oral doses have been ineffective.

Glutathione is naturally synthesized in the brain from three amino acids. Dr. Ludeman’s role is to synthesize molecules related to these “building blocks,” or prodrugs, which are more readily transported across the blood brain barrier. The prodrugs contain a “label” which can be visualized through MRI techniques. Working with rats, the team uses brain imaging to non-invasively follow the uptake and conversion of these prodrugs to glutathione.

Over the years, Dr. Ludeman has worked closely with researchers with many different areas of expertise and from all over the world to come up with some innovative treatments, several of which she holds patents on.

One project at Johns Hopkins resulted in Gliadel™, a clinically used drug delivery system for brain cancer. Gliadel is a dime-sized wafer composed of a polymer which slowly releases an anticancer agent. Multiple wafers are implanted in the cavity left after a surgeon removes as much of a brain tumor as possible; the purpose of the implant is to release drug directly at the site of any remaining cancer cells. The project was a multi-disciplinary effort involving neurosurgeons, oncologists, chemical engineers, polymer chemists, organic chemists, pharmacologists, biologists and representatives from the pharmaceutical industry.

“Working in a medical center you get to see the impact of your projects and how important collaborations between different disciplines are,” says Dr. Ludeman.

Another patent derived from chemistry, cell biology and pharmacology is for a dye that detects certain types of stem cells by causing them to light up under spectroscopy. Once isolated from, for example, marrow or cord blood, these stem cells can be injected into the patient in the hopes of a therapeutic response such as tissue regeneration or a treatment for leukemia.

The dye is commercially available for research purposes and cells isolated using this dye are being tested as part of regenerative tissue therapies in clinical trials at medical centers around the United States.

PrezRepVF

4/15/09

1:35 PM

Page 7

ACPHS 2008

Susan Ludeman’s research involves the chemistry and pharmacology of cyclophosphamide (known clinically as Cytoxan™) and related alkyating agents. Shown is an energy-minimized, van der Waals surface structure of cyclophosphamide (ChemDraw 3D).

“It is performing well in a major clinical trial with people who are in danger of losing their limbs,” explains Dr. Ludeman.

After spending the fall semester setting up her new lab, Dr. Ludeman is ready to get students involved in her research and has three, including one freshman, signed on for the spring.

“The interdisciplinary nature of Dr. Ludeman’s work provides students an excellent opportunity to participate in cutting-edge research that spans the fields of chemistry, biochemistry and pharmacology,” says David Clarke, Ph.D., Arts and Sciences department chair.

“My own undergraduate research experience ignited my excitement for chemistry and became the springboard for my decision to enter graduate school and pursue an academic career,” Dr. Ludeman says. “I am a huge proponent of undergraduates being given the opportunity to discover their own interests and paths.

It’s exciting to see students make something that has never been made before.”

Dr. Ludeman demonstrates a rotary evaporator to Mike D’Alessandro, a second-year student in the Pharmaceutical Sciences program.

Dr. Ludeman holds a patent on an assay for detecting certain types of stem cells. The assay is known commercially as Aldefluor™ and its key component is a dye known as BODIPY aminoacetaldehyde.

This dye, which was designed by Dr. Ludeman, is shown as an energy-minimized, van der Waals surface model (ChemDraw 3D).

// 7

PrezRepVF

4/15/09

1:35 PM

Page 8

PrezRepVF

4/15/09

1:35 PM

Page 9

ACPHS 2008

// 9

The Department of Health Sciences at ACPHS expanded in many exciting directions in 2008. The department made significant progress toward the complete implementation of the three tracks within the B.S. in Biomedical Technology program: Clinical Laboratory Science (CLS), Cytotechnology and Physician Assistant Studies, further enhancing the range of academic programs now offered at the College.

Putting the Health Sciences into ACPHS Growing Enrollment, Expanded Programs

With students now in all four years of the program and every course in all three tracks offered for the first time, several new part-time faculty members were added to the department during the year, joining associate professors Indra Balachandran, Ph.D., and Elyse Wheeler, Ph.D.; Assistant Professor Victoria Peters, M.S. Ed.; and Instructor Joe Walker, B.S. In addition, Lawrence Lansing, M.D., has joined the department in a full-time capacity. A Board Certified Pathologist and active researcher, Dr. Lansing brings a unique clinical insight to the classroom.

More courses were added as well. The CLS program alone implemented 11 new courses and associated labs in 2008 including classes in advanced hematology, immunohematology and molecular techniques.

Both the cytotechnology and the clinical laboratory sciences tracks have graduated their first bachelor’s degree students while five students received post-baccalaureate Certificates in Cytotechnology. All of the graduates passed the American Society of Clinical Pathology Registry exam required to work as cytotechnologists and are employed in hospitals and private labs.

The University of Rochester Medical Center, New York Presbyterian Hospital and Long Island Jewish Medical Center were added as new clinical affiliations, providing additional opportunities for students in the cytotechnology program.

Currently, there are more than 20 clinical affiliates in hospitals and private laboratories in the Capital District and across the country.

The program has grown not only in size, but also has acquired some crucial new equipment. Since moving to the cytotechnology classroom at the College’s facility at 84 Holland Ave., the student experience has been enhanced by the addition of a ThinPrep T2000 processor made possible with a grant from the Bender Family Foundation and the help of Hologic. ThinPrep is one of two FDA-approved methods for making liquid-based preparations of specimens in a cytology lab. With the new processor, the program can increase teaching cases of ThinPrep material and offer hands-on experience to students.

In addition, the program has received support from BD Tripath to increase SurePath cases, another method of making liquid-based gynecologic, non-gynecologic and fine needle aspirations.

A multi-headed review scope received from Albany Medical Center helps faculty to demonstrate the criteria for diagnosis of infections, pre-malignant changes and malignancies simultaneously to nine students. It is also used extensively for reviewing students’ unknown cases.

“In this format, each student learns from, not only his or her unknown cases, but also from those of their classmates,” says Dr. Balachandran, director of the cytotechnology program. “This, in turn, increases the students’ confidence in criteria and diagnosis of disease processes.”

The CLS program has made progress this year as well, completing its self-study, a major step toward receiving accreditation by the National Accrediting Agency for Clinical Laboratory Science (NAACLS).

PrezRepVF

4/15/09

1:35 PM

Page 10

Clinical Laboratory Sciences Director Vickie Peters spends a great deal of time in the lab with students.

“The Clinical Laboratory Science program has achieved ’Serious Applicant’ status through the NAACLS, which allows our students to sit for certifying and licensing exams,” says program director Vickie Peters. “Full accreditation is expected by May of 2009.”

The program is also finalizing affiliation agreements with Hudson Valley and Schenectady Community Colleges.

ACPHS also offers a unique program with Albany Medical College’s (AMC) Center for Physician Assistant Studies. The joint program begins at ACPHS with academic preparation and training in basic science and a clinical labo-

ratory specialty. Upon completion, in January of their senior year, students enter a two-year M.S. program in Physician Assistant Studies at the Medical College. The program offers an excellent pathway for students seeking to “lock in” one of the coveted spots in AMC’s highly competitive physician assistant program.

The department promises to grow even more during the 2008–2009 academic year. Hassan El-Fawal, Ph.D., has joined the College as the new chair of Health Sciences. Dr. El-Fawal received his B.Sc. in Entomology and Pesticide Chemistry from the University of Alexandria, Egypt, M.Sc. in Biomedical Sciences from University of Guelph, Canada, Ph.D. in

Biomedical and Environmental Sciences from Virginia Polytechnic Institute and State University and postdoctoral fellowship at the USEPA in Research Triangle Park, N.C. A specialist in the area of toxicology, he previously worked at Mercy College School of Health

PrezRepVF

4/15/09

1:37 PM

Page 11

ACPHS 2008

Professions and Natural Sciences and New York University School of Medicine. His full-time appointment as professor and chair of Health Sciences took effect in January. He also holds a joint appointment in the Department of Pharmaceutical Sciences.

With more than 20 years of academic and research experience, Dr. El-Fawal does not hesitate to cross lines between the humanities and the basic and applied sciences. He has developed and taught biomedical curricula for such diverse programs as Physical and Occupational Therapy, Communication Disorders, Physician Assistant Studies, Acupuncture and Oriental Medicine, Nursing and Clinical Laboratory Sciences. In addition he has mentored students in Neuroscience, Pharmacology and Environmental Medicine.

Dr. El-Fawal was attracted to ACPHS because of its “entrepreneurial spirit and mission to provide a quality education in an environment hospitable to students and researchers, alike.” He is particularly impressed by the College’s accomplishments and growth, both physically and intellectually, in the past decade though efforts such as PRI, graduate degree offerings and the ability to attract cutting-edge researchers.

“The College is poised to write a new chapter in biomedical advancement and education.” He sees himself a part of that vision.

“We are defining Health Sciences in the broadest sense, establishing a foundation that is inclusive of such cutting-edge growth fields as biotechnology, molecular diagnostics, immunotechnology and environmental health, as well as being at forefront of clinical diagnostics,” says Dr. El-Fawal. “The cornerstone of this foundation is to be student-centered and build an intellectual partnership between faculty, students and the institution. ACPHS has the intellectual capital, the will and the energy to be a pioneer in biomedical education.”

A ten-headed microscope allows Joe Walker, education coordinator for cytotechnology, and students to simultaneously review cases.

// 11

PrezRepVF

4/15/09

1:37 PM

Page 12

Going Global

Across the globe, pharmaceutical researchers, instructors and students are getting a glimpse of the work being done at Albany College of Pharmacy and Health Sciences. At the same time, they’re sharing their knowledge with ACPHS students, faculty and researchers. The surge in international exchanges around the world bodes well for the future of medicine and the treatment of major illnesses.

PrezRepVF

4/15/09

1:37 PM

Page 13

ACPHS 2008

Doing pharmaceutical research with scientists from other countries has numerous benefits, says Shaker Mousa, Ph.D., executive vice president and chairman of the Pharmaceutical Research Institute at ACPHS. Under Dr. Mousa’s direction, the Institute has obtained dozens of research grants and equipment donations totaling more than $13 million since its establishment in 2002. Now located in a spacious facility in Rensselaer, N.Y., PRI has grown from three employees to 48 over the past five years, with international experts in fields such as nanotechnology, medicinal chemistry, molecular biology, cell biology and drug delivery and development on staff.

“Our research collaborations bring international recognition to the College and will draw graduate students to ACPHS from all over the world,” says Dr. Mousa, a native of Egypt and the

founding director of PRI. “They make people aware of our educational and research capabilities while attracting scientists who bring new dimensions to our work.”

// 13

THE MIDDLE EAST

Collaborations help pharmaceutical researchers fulfill their ultimate goal: the advancement of science. “The goal at the end of the day is to save human lives,” Dr. Mousa says. “Science has no boundaries, particularly when it comes to benefiting mankind . Diversity and partnerships are our greatest chance for success.”

One of the many collaborations now underway involves work with researchers in the Middle East on new approaches for treating breast cancer. Breast cancer kills millions of women around the world each year and affects millions more. In the course of treatment, some women become resistant to chemotherapy. Others become very ill from the systemic effects of anti-cancer drugs.

Over the past five years, Dr. Mousa has developed national and international collaborations with academic, pharmaceutical and biotechnology institutes in the U.S., Japan, South Korea, Saudi Arabia, Kuwait, the United Arab Emirates, Egypt, Germany, France, England, Turkey, Denmark, Australia, India and others.

“We are trying to overcome the resistance problem, so that the chemo can still be effective,” Dr. Mousa explains. “We’re also using nanotechnology to deliver chemo directly to the cancer cells, so we can eliminate the horrible side effects that result from the destruction of healthy cells.”

Dr. Murat Yalcin from Uludag University in Turkey, shown here with ACPHS students Evan Kujawski and Rebecca Reynolds, has assisted PRI with breast cancer research.

PrezRepVF

4/15/09

1:37 PM

Page 14

Panorama of a slide showing breast adenocarcinoma, viewed under a microscope.

That’s where Olfat Shaker, M.D., came in. Dr. Shaker, a professor of medical biochemistry and molecular biology at Cairo University in Egypt, was a visiting scholar at PRI in 2008.

Researchers at PRI provided technical support and advice on nanoparticle formulations, while Dr. Shaker offered data on tumor growth, tumor angiogenesis and the impact of antitumor agents on body organs. Their collaboration will produce agents that will be tested on animals, with the hopes of advancing to human trials one day. The technology will also be applied to liver cancer.

A jumbled mass of cancer forces its way in healthy liver tissue in this microscopic view.

“We are starting to publish our joint works,” Dr. Mousa says. “The next step is for us to go to Egypt, where the incidence of liver cancer is very high, to examine novel targets in liver cancer models and learn about the research taking place there.”

(NACH) compounds and the delivery of chemotherapy into breast cancer cells with minimal impact on normal cells. During treatment, these compounds may reduce the risk of blood clotting, which is one of the most significant and deadly side effects of chemotherapy.

Dr. Mousa also has the help of another overseas researcher in a separate breast cancer project, funded by a $406,400 grant from the United States Department of Defense. Murat Yalcin, Ph.D., a veterinarian researcher from Uludag University in Bursa, Turkey, is here to assist with research into non-anticoagulant heparin

PRI is also exploring the use of low molecular weight heparin (LMWH) derivatives in the treatment of renal cancer with researchers at several universities in Dubai and Kuwait, where the disease is more common than here in the U.S. “There is direct evidence that these drugs have an anti-cancer effect and that the anti-

Dr. Olfat Shaker, left, a professor of medical biochemistry and molecular biology from Cairo University in Egypt, shown here with ACPHS student Anhtung Duong, visited PRI to share expertise in the areas of tumor growth and angiogenesis.

PrezRepVF

4/15/09

1:37 PM

Page 15

ACPHS 2008

clotting effect is a secondary benefit,” Dr. Mousa says.

The Institute’s work with LMWH derivatives includes treating pain in patients with sickle cell disease, an inherited blood disorder that causes abnormal hemoglobin and disrupts blood flow.

Sickle cell disease affects as many as 3 in 10 people in Saudi Arabia as well as about 50,000 people in the U.S., most of them AfricanAmerican.

Findings from that research—which was dubbed a “landmark study” by the American Hematological Society—helped create guidelines for managing pain in sickle cell patients.

“We’re now doing a follow-up trial that will show how to give home treatments for the painful crisis,” Dr. Mousa says. “Now, instead of going to the hospital to get an injection, we’re coming up with a formula that patients can self-administer at home.”

The sickle cell studies and other studies in the United Arab Emirates have spawned the promise of another type of collaboration—providing ACPHS faculty with the chance to teach continuing education classes and workshops to pharmacy graduates in Dubai. “It would a great opportunity for our faculty,” Mousa says. “It would be major exposure for the College, and we would be teaching graduates from all over the world.”

WORKING IN THE WEST The Middle East is only one region of the world working with PRI researchers. The institute is also collaborating with scientists at the University of Frankfurt in Germany. According to Dr. Mousa, German scientists are very advanced in embryonic stem cell research, which may someday be used to treat vascular diseases and thrombosis, repair tissue damage caused by spinal cord injuries and trauma and possibly even cure diabetes and other autoimmune diseases.

Dr. Mousa says he hopes to combine nanotechnology with non-embryonic stem cell research to create a delivery system that will implant the

// 15

Anthrax bacteria are rod-shaped and highly pathogenic. Two forms of the disease occur: in the lungs and on the skin. The skin infection is usually treatable with antibiotics. Inhalation of anthrax spores and the development of pulmonary anthrax is often fatal unless antibiotics can be administered before the symptoms appear.

stem cells with the least amount of side effects.

Stem cells will then help regenerate tissue that will help repair damaged tissue including nerves, blood vessels and bones. “We could potentially repair the heart in people with heart failure,” he adds.

That same enthusiasm is being directed at another project that seeks to reverse vision loss in people with diabetes and macular degeneration. Joining PRI researchers in that endeavor is Evgeny Dyskin, M.D., who earned his Ph.D. from the Medical Radiological Research Centre in Obninsk, one of Russia’s leading scientific centers. Dr. Dyskin is continuing his ophthalmology research at PRI and testing novel anti-angiogenesis targets that prevent and reverse vision loss in patients with diabetic retinopathy and macular degeneration.

Closer to home, PRI is part of a joint project with the University of Toronto, Rensselaer Polytechnic Institute and Biophage Pharma Inc., a Canadian company, to develop an antidote for anthrax, a potentially deadly disease caused by the naturally occurring Bacillus anthracis bacterium. The group recently received a fiveyear $6.2 million grant for the project, of which PRI will receive $1.37 million.

The PRI research team will focus on optimizing the concentrations of ’ingredients’ in the antidote and look for ways to extend the product’s shelf life. Though anthrax sometimes can be treated with antibiotics, some forms of the disease are resistant to any form of therapy. An antidote would provide an additional form of treatment, one that might be more effective in the latter stages of the disease when standard treatments are less effective.

The project has also received the assistance of ophthalmology and biotechnology researchers from Showa University in Tokyo, Japan, who spent three months at PRI.

Stem cells can differentiate into any other cell type. There are three main types of mammalian stem cell: embryonic stem cells, derived from blastocysts; adult stem cells, which are found in some adult tissues; and cord blood stem cells, which are found in the umbilical cord.

PrezRepVF

4/15/09

1:38 PM

Page 16

Dr. William Millington is working with scientists from Turkey on the role of the brain chemical glycyl-glutamine in preventing drug addiction.

WORLD-WISE RESEARCH AND LEARNING International research is happening in the laboratories on campus, as well; a reflection of the pharmaceutical industry’s efforts to do more global research and the College’s drive to provide students a more worldly education.

central nervous system mediates the initiation of septic shock and how prenatal immune challenges, such as stress and infections, affect behavior during adulthood. Their work has been published in several journals.

Carlos Feleder, M.D., Ph.D., an assistant professor in the Department of Pharmaceutical Sciences, has been working with Xiujuan Yao, a Ph.D. candidate from the China Pharmaceutical University in Nanjing. Yao is at ACPHS for two years on a fellowship to supervise research activities related to a grant Dr. Feleder received from the National Institutes of Health to study the role of the spleen in managing fever (see page 8).

Dr. Feleder is also working with M. Sertac Yilmaz, M.D., Ph.D., a visiting scientist from Uludag University School of Medicine in Bursa, Turkey. Together with William Millington, Ph.D., chair of the Department of Pharmaceutical Sciences, they are studying and publishing articles on the role of the brain in septic and hemorrhagic shock. Along with another scientist from Uludag University, they are planning a symposium on the topic at a scientific meeting in Antalya, Turkey, in November 2009.

In addition, Dr. Feleder is working with Rodolfo Cutrera, Ph.D., a professor in the Department of Physiology at the University of Buenos Aires in Argentina. Their research is looking at how the

Separately, Dr. Millington has been working with Sinan Cavun M.D., Ph.D., and Gokhan Goktalay, M.D., Ph.D., associate professors of

Ophthalmology and biotechnology researchers from Showa University in Tokyo, shown here with Dr. Shaker Mousa and ACPHS President James J. Gozzo, spent three months at PRI on cutting-edge research to reverse vision loss in people with diabetes and macular degeneration.

pharmacology at Uludag. The trio is studying a brain chemical called glycyl-glutamine (Gly-Gln) and its role in the prevention of addiction to drugs such as nicotine and morphine. Their research on rats has shown that Gly-Gln reduces the effects of morphine and nicotine and the severity of withdrawal from these drugs.

Dr. Cavun has taken the research even further in Uludag, using microdialysis techniques not available at ACPHS. “He showed that Gly-Gln inhibits the euphoria that a morphine high produces by preventing the morphine-induced release of dopamine in the brain reward pathway,” Dr. Millington says. Meanwhile, Dr. Goktalay is in Ankara, Turkey, testing whether Gly-Gln is effective in animal models of anxiety and epilepsy.

Another faculty member working with international researchers is Robert M. Levin, Ph.D., professor of pharmaceutical sciences. Most of Dr. Levin’s research is in lower urinary tract function and dysfunction in both males and females. He has worked with several scientists from Maruzen Pharmaceuticals of Hiroshima, Japan to study the use of kohki tea for the treatment of urinary bladder dysfunction due to an enlarged prostate. Kohki is a leaf rich in antioxidants that comes from a plant in China, and is formulated into a medicinal tea by Maruzen.

Dr. Levin also works with other international researchers from Taiwan, Korea and China on studies involving lower urinary tract dysfunctions including incontinence and interstitial cystitis in women.

Still to come is a new venture between Luciana Lopes, PhD., an assistant professor of pharmaceutical sciences at ACPHS, and Maria Vitoria Bentley, Ph,D. of the Pharmacy School of Ribeirao Preto at the University of Sao Paulo in Brazil. The two researchers will study the development and characterization of new transdermal delivery systems. Jaclyn Hosmer, a Pharm.D. student at ACPHS, is also involved in the research (see story page 20).

PrezRepVF

4/15/09

1:38 PM

Page 17

ACPHS 2008

// 17

Extracts of tea leaves have been used medicinally in East Asia for hundreds of years. Dr. Robert Levin has worked with scientists in Japan to study their use to treat bladder dysfunction.

MORE STUDENTS ABROAD At the same time, more and more ACPHS students are studying at foreign universities.

ACPHS already has programs with the University of Basel in Switzerland and Maruzen Pharmaceuticals and is working on developing more.

In Basel, for example, sixth-year Pharm. D. students engage in clinical testing at the University Hospital and gain experience working in Swiss hospitals and retail pharmacies. They also spend time at a heroin clinic, visit corporations like Roche and Novartis and complete research projects that, in some cases, result in publications, says Kevin Hickey, Ph.D., an assistant professor in the Department of Arts and Sciences, who has overseen the program since 2004. In exchange, Dr. Hickey invites students from Basel to do research with ACPHS faculty. “The hope is that this partnership will grow into not only more student exchanges, but also faculty collaborations and exchanges and innovative teaching technologies such as sharing lectures via video-streaming,” he says.

Over in Hiroshima, Japan, students have the chance to do research at Maruzen Pharmaceuticals, a company specializing in natural products. Since 2001, Dudley Moon, Ph.D., professor of biological sciences, has coordinated a five-week internship for ACPHS students at Maruzen R&D Centers. The experience, which also meets the requirements for a Pharm.D. rotation, kicks off with study of the Japanese language.

Anna Leung, 23, of New York City, had the opportunity to go to Maruzen in the summer of 2008. While there, she did research on natural products. “We extracted, purified and tested chemicals from plants,” she said. “After work hours, the staff was kind enough to show us around. There were also many cultural events organized to help us experience Japan.”

Even with these well-established programs, the College continues to forge new ties and, in coming months, will offer students the chance to study at the University School of Pharmacy in Yeditepee, Turkey, and Uludag University

School of Medicine in Bursa, Turkey. The college is also on the brink of establishing exchanges with the National University of La Plata, School of Pharmacy, in Argentina; the University of Belgrano, School of Pharmacy, in Buenos Aires, Argentina and the University of Santiago de Compostela, School of Pharmacy, in Spain.

to build ties to Fudan University in Shanghai and hoping to create education and research opportunities for graduate students and rotations for Pharm.D. students. “We want to try and send graduate students to China to study traditional Chinese and herbal medicine,” he says.

“We are developing joint training programs for both undergraduate and graduate students, whereby we will exchange students and faculty,” Dr. Feleder says. “We will also apply for a grant for the project from the European Union, which provides support for these kinds of interactions between universities.”

Meanwhile, in the Department of Arts and Sciences, Assistant Professor Ray Chandrasekara, Ph.D., is working to establish research and rotation opportunities for ACPHS students in Southeast Asia, most notably Cambodia and Vietnam, especially for students interested in going on to medical school.

“These experiences are eye opening and would set them apart from other students,” Dr. Millington says.

For his part, Andy Zheng, Ph.D., an assistant professor of pharmaceutical sciences, is trying

A Japanese tea ceremony was one of the highpoints of the Nature-ceuticals Symposium held at ACPHS in June 2008.

Working with international scientists creates other possibilities too. Last June, the connection with Maruzen gave rise to the first-ever Nature-ceuticals Symposium at ACPHS. According to Dr. Moon, chair of the event’s organizing committee, the conference exposed faculty and students to natural products, which have long been an important part of Japanese culture and are becoming increasingly popular among U.S. consumers. Highlights of the event included a keynote address by David M. Eisenberg, director of the Division of Research and Education in Complementary Medicine at Harvard Medical School and a Japanese tea ceremony. Dr. Moon hopes to stage another conference in 2011.

“To be truly educated, students should have a global perspective,” says Dr. Millington.

Based on the number of collaborations in place and under development, an increasing number of students at ACPHS are now gaining that global perspective—both scientifically and culturally. The result is graduates who leave the campus with a greater sense of themselves and the world around them.

PrezRepVF

4/15/09

1:38 PM

Page 18

There’s a killer on the loose in our hospitals and schools. Dr. Thomas Lodise and researchers at ACPHS and across the country are looking into ways to combat a deadly staph infection.

Tackling a Serious Public Health Concern Lodise teams with ACPHS faculty and other collaborators on MRSA research

Dr. Lodise, an associate professor in the Department of Pharmacy Practice at ACPHS, has received four grants totaling $469,598 to study methicillin-resistant staphylococcus aureus (MRSA) and the various antibiotics used to treat infections from this potentially deadly bacteria.

“The dramatic increase in MRSA infections— in both health care and community settings— is a cause for great concern for health care practitioners,” says Dr. Lodise. “One of the goals of this research is to determine the best course of treatment for patients infected with MRSA.” MRSA is a type of staph infection that is demonstrating increased resistance to the medications typically prescribed to treat it.

According to the National Institutes of Health (NIH), “MRSA has evolved from a controllable nuisance into a serious public health concern.”

MRSA can present in two forms. The first, Health Care Associated MRSA, is common in settings such as hospitals and nursing homes and among people with weakened immune systems. Community Associated MRSA, which infects otherwise healthy people, is usually found in settings where there is close contact among people, such as schools. The death rate from an MRSA infection ranges from 20–30 percent and survivors are susceptible to recurrent infections, slower response times to treatments and longer hospital admissions.

Dr. Lodise is working with Nimish Patel ’06 to develop dosing guidelines for patients with MRSA who are undergoing dialysis.

As the principal investigator on a $48,225 grant from the Foundation for Healthy Living, Dr. Lodise will examine different strains of Health Care Associated MRSA and determine against which ones vancomycin, the drug typically prescribed for treating MRSA, is likely to be the most effective. He will be assisted in his work by collaborators from Albany Medical Center, the Buffalo V.A. Medical Center and Strong Memorial Hospital in Rochester.

The team will identify different biological markers within each strain of Health Care Associated MRSA and study how individual strains respond to treatment with vancomycin. Ultimately, their research will help health care professionals make more informed decisions on the best courses of treatment for MRSA patients. The study is believed to be the first of its kind to examine these types of markers in a statewide fashion.

Sufferers of chronic kidney disease (CKD) are particularly susceptible to MRSA infections.

Between 1995 and 2002, dialysis centers reported that the increase in incidences of MRSA soared from 40 to 76 percent, with vancomycin-resistant cases more than doubling.

Daptomycin, a new alternative to vancomycin, may prove more successful in treating MRSA in patients with CKD. But because drugs behave differently in the bodies of patients being treated with dialysis versus healthy adults, it is difficult to know the appropriate dosing of daptomycin. Without proper dosing guidelines, dialysis patients may be exposed to either excess medication or inadequate doses.

A $241,717 grant from Cubist Pharmaceuticals will help Dr. Lodise and co-investigator Darren Grabe ’95, Pharm.D., an associate professor in the Department of Pharmacy Practice, study patients undergoing hemodialysis—a procedure used by nearly two-thirds of all sufferers of end-stage kidney disease—and employ mathematical modeling to determine the optimal dosing requirements of daptomycin.

Dr. Lodise and Dr. Grabe are working together with Katie Pallotta ’06, Pharm.D., and Nimish Patel ’06, Pharm.D, from ACPHS, and Chris Hoy, M.D., and Shari Meola, RN, from the Hortense and Louis Rubin Dialysis Center, the outpatient clinic used in the study.

PrezRepVF

4/15/09

1:38 PM

Page 19

ACPHS 2008

A third antibiotic used to treat MRSA is linezolid, but many health care professionals choose not to prescribe this medication, as it may lead to Serotonin Syndrome in people who take antidepressants. The syndrome may result in changes in mental state, as well as neuromuscular disorders and overall body hyperactivity.

Because published data supporting increased incidence of Serotonin Syndrome among patients taking both linezolid and antidepressant medications remain sparse, there is some dispute about whether these drugs will interact in a manner likely to cause the syndrome.

Patients who might react favorably to linezolid may be prescribed a less effective course of treatment to avoid the possibility of negative side effects.

With a $25,000 grant from Pfizer, Dr. Lodise will study the probability of linezolid and antidepressant drugs reacting in a manner that will result in Serotonin Syndrome. If a connection can be found, additional research will be done to determine if certain patient populations are

// 19

at higher risks than others for this outcome.

While the presence of MRSA in health care environments is not new, its expansion in community settings is a recent and disturbing development. Outbreaks across the country have made national headlines, and the trend shows no sign of abating.

Today, more than half of all skin and soft tissue infections are caused by MRSA. Most of these patients are treated with antibiotics in an outpatient setting, where a drug is typically delivered intravenously over a period of 10–14 days.

With a $154,656 grant from Cubist Pharmaceuticals, Dr. Lodise will team with Leon Cosler ’82, Ph.D., director of the Research Institute for Health Outcomes at ACPHS, to review a health claims database of patients treat-

Strains of MRSA (Methicillin-resistant Staphylo-coccus aureus) bacteria, shown here dividing, are increasingly resistant to many antibiotic drugs.

ed for skin and soft tissue infections to examine the effectiveness of vancomycin, daptotmycin and linezolid, and determine if one of these medications provides superior outcomes in treating Community Associated MRSA infections.

“As the number of MRSA cases continues to multiply across the country, the findings of these research projects will hopefully help inform health care professionals on how to better treat afflicted patients and minimize their suffering.”

PrezRepVF

4/15/09

1:38 PM

Page 20

Third-year Pharm.D. student Jaclyn Hosmer ’12 has teamed with Assistant Professor Luciana Lopes in groundbreaking research that will hopefully lead to a new treatment—with fewer negative side effects—for various types of skin cancer.

Skin deep Topical treatment offers new possibility for delivering anti-cancer drugs

The work being conducted by Dr. Lopes, with the assistance of Jaclyn, focuses on the development of liquid crystalline phases containing the anti-cancer drug paclitaxel for the topical treatment of cancers.

The research is particularly important to Jaclyn who, as one of the first students to enter enroll in the College’s new master’s degree program in Pharmaceutical Sciences (MSPS) this fall, will pursue her Pharm.D. and MSPS degrees at ACPHS simultaneously.

Liquid crystalline phases observed under a polarized light mircoscope.

Lamellar phase

“Medical research is something I have always wanted to do and this will give me more flexibility than a Pharm.D. alone,” Jaclyn says. “My career goal is to work in the industry, developing drugs or delivery systems.”

“It doesn’t look like much, but when you get it under a microscope, it looks really cool,” adds Jaclyn. “If we can treat the cancer topically and just get the drug to stay on the skin, we may be able to significantly reduce the side effects.”

Paclitaxel is a chemotherapeutic agent used to treat several types of cancer. Though it can be effective in treating skin cancers, including Kaposi’s Sarcoma and basal cell carcinoma, severe side effects have limited its usefulness.

Jaclyn, who has worked with Dr. Lopes over the past two academic years, says that there is not much in the literature about the topical use of paclitaxel. Her role in their pioneering research currently involves in vitro studies utilizing the skin from pigs’ ears; she then measures the results using high-performance liquid chromatography.

Many HIV/AIDS patients suffer from Kaposi’s, which is characterized by skin lesions that may spread to the mouth, gastrointestinal tract and respiratory tract. Presently, the disease is treated intravenously with paclitaxel with resultant side effects such as low platelet count, hair loss and joint pain. Hoping to overcome the drug’s limitations, Jaclyn is assisting Dr. Lopes in developing strategies to deliver paclitaxel directly to the skin, and only the skin, via a liquid crystalline phase, as this may optimize drug localization within skin lesions while eliminating the adverse effects.

“We are currently developing liquid crystalline systems to enhance the penetration and localization of paclitaxel in the skin while reducing its transdermal delivery,” says Dr. Lopes. “Liquid crystalline phases consist of the state of matter whose properties are intermediate between a crystalline solid and a liquid. They look similar to gels, but they have a very organized internal structure.”

Hexagonal phase

Typically, Jaclyn spends about 10 hours per week in the lab, working on experiments either with her mentor or by herself. This summer, the team will commence in vivo research with rats.

Eventually Jaclyn says their work may focus on attaching paclitaxel to peptides to deliver the drug directly to the tumor site.

Last April, Jaclyn made a poster presentation, which was considered for an award, at the 11th Annual American Association of Pharmaceutical Scientists Northeast Regional Discussion Group. The team recently submitted an abstract to the Annual Meeting of the Controlled Release Society, which will take place in Copenhagen this July, and are hoping to present there as well.

“Jackie is very smart and learns things very fast,” Dr. Lopes says. “She is focused, committed and hard-working—qualities which will allow her to excel in her professional life and become an outstanding scientist!”

Assistant Professor Luciana Lopes and student Jaclyn Hosmer are working to develop liquid crystalline systems to enhance the effectiveness of the anti-cancer drug paclitaxel.

PrezRepVF

4/15/09

1:40 PM

Page 21

ACPHS 2008

// 21

PrezRepVF

4/15/09

1:41 PM

Page 22

SCIENTIFIC METHOD

Enrichment Programs Inspire Next Generation of Scientists

Taylor Lanoue of Averill Park High School performs a research experiment at PRI while Berne-Knox-Westerlo student Justin Coon compiles the results.

Dr. Shaker Mousa, executive vice president and chairman of the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, in the lab with students Sabith Choudhury of Hudson High School and Elizabeth Derderian of Averill Park High School.

PrezRepVF

4/15/09

1:41 PM

Page 23

ACPHS 2008

Albany College of Pharmacy and Health Sciences believes strongly that part of its responsibility as an institution of higher learning is to foster and develop an interest in science among children.

The College now offers three science enrichment programs for students ranging from third grade to seniors in high school. The newest of these programs is the High School Research Program which takes place throughout the school year at the College’s Pharmaceutical Research Institute (PRI).

This year, PRI will host more than 40 seniors from 11 high schools across the Capital Region.

Shaker Mousa, Ph.D., executive vice president and chairman of PRI, explains that shortly after the Institute was founded in 2003, he began to receive requests from friends and colleagues who were interested in having their sons and daughters participate in research at the Institute. He happily obliged, and before long, word began to spread among students and teachers at high schools across the region about this unique opportunity to work under the direction of accomplished investigators.

“When schools contact me and say they are looking to place students at PRI, I can’t say no.

I would feel miserable if I turned away someone who was interested in science. The child that I turn away might be the one who finds a cure to a disease and saves thousands of lives.” says Dr. Mousa.

Depending on the individual school, students in the research program are at PRI for six hours per week for six weeks or four hours per week for eight weeks. On the first day, Dr. Mousa meets with them to discuss the parameters of their projects, which may involve experimenting with various types of medicines to compare their effectiveness. Working in pairs, students spend the first week orienting themselves to the labs and learning basic research methodologies before starting their projects. Students are taught to work independently after the first week, though research manager Majde Takieddin remains nearby to supervise their activities, answer questions and monitor their progress.

During the course of these sessions, they are expected to gather, graph and analyze their research data. In June, all of the students return to PRI to formally present their findings to an audience comprised of their parents, teachers and peers.

“Many parents watch in disbelief as their children present and defend their research,” says Dr. Mousa. “They tell me, ’I can’t believe that those words came from my child’s mouth!’”

Some of the students feel the same way. “I definitely didn’t think I could do this at the beginning of the year,” said Andrea Nero, a student in 2007–08 program. “If I had seen the poster I created, I would have thought that I could never do something like that. But it is possible.”

The forerunner to the PRI program is the High School Summer Research Program, an annual program which marked its tenth year at ACPHS this past summer. The program, in which rising high school juniors and seniors pursue research on campus, is overseen by David Clarke, Ph.D., chair of the Department of Arts and Sciences.

Five students from Albany and Troy High Schools were selected to participate in the 2008 session.

In addition to the daily research activities, the six-week program features “field trips” to science and technology facilities such as Albany

// 23

Medical Center, Albany Molecular, Regeneron and Mallinckrodt. ACPHS faculty assisting with this year’s program included Dr. Mousa as well as Carlton Campbell, Ph.D., Leon Cosler, Ph.D., Martha Hass, Ph.D., Luciana Lopes, Ph.D., Abdelhadi Rebbaa , Ph.D. and HaiAn Zheng, Pharm.D. As with the PRI program, students in the summer program must present their research to a gathering of faculty and staff and answer questions related to their findings and methodologies.

“Through the participation of numerous ACPHS faculty and students as well as the cooperation of local companies, the Summer Research program is able to showcase the many opportunities available to students in the world of scientific research. Without this type of exposure, it is difficult for young people to understand the range of exciting careers in the sciences,” says Dr. Clarke.

At the opposite end of the age spectrum is the ACPHS Academy program, which offers a mathematic and scientific enrichment program for local, at-risk students beginning in the third grade and continuing through high school.

The program is designed to encourage students at an early age to succeed and to build confidence academically, particularly in math and science. Reciprocally, ACPHS students benefit by serving as mentors to these children, an experience which helps enrich their overall education and professional development.

The program was launched in 2006 with a third-grade class from nearby Delaware Community School. Students from that class, now in fifth-grade, are matriculating through the program, and this year they were joined by a new class of third-graders from the Brighter Choice Charter School. The participation of students from Brighter Choice was made possible through a gift of $250,000 from Thomas D’Ambra, Ph.D., president and CEO of Albany Molecular Research, and his wife, Connie.

The importance and need to fund these programs and others like them cannot be overstated.

“There is a crisis that exists in the U.S. when it comes to getting young people interested in science and technology. This is the greatest country when it comes to technology, but we are in a major decline, while countries such as China and India are on the rise,” says Dr. Mousa.

“If we lose on science and technology, what is left for us? We don’t want to reach that level.”

PrezRepVF

4/15/09

1:41 PM

Page 24

Gateway to Research

STUDENT RESEARCH

STUDENTS RECEIVE PRESTIGIOUS SCHOLARSHIPS

Awards Program Recognizes Student Research Each summer, the Student Summer Research Award Program at Albany College of Pharmacy and Health Sciences awards internships that provide a $2,000 stipend and free dormitory housing to students in any of the degree programs at the College. This past summer, 10 students participated in the highly competitive, eight-week program.

An awards ceremony held on October 3, during Family Weekend, allowed members of the ACPHS community and parents an opportunity to see research presentations from participating students.

Leona Blustein, a sixth-year student, worked with faculty mentor Sara Dugan, Pharm.D., to do an assessment of substance use and abuse among pharmacy students. Faculty members Nicole Lodise and Jen Cerulli also assisted.

Leona, who hopes to do a general residency or fellowship in psychiatry after earning her Pharm.D., found that pharmacists are often poorly trained to deal with alcohol and drug abuse, and there is a need for more education in this area.

Amanda Dihmess and Tom Lodise, Pharm.D., worked together on the molecular and clinical epidemiology of carbapenem-resistant enterobacteriaceae. Carbapenems are a mainstay in therapy against infections caused by gramnegative bacteria. Amanda hopes to publish her findings in the spring.

Third-year student Jaclyn Hosmer teamed with Luciana Lopes, Pharm.D., Ph.D., on the development of microemulsions containing paclitaxel for the topical treatment of Kaposi’s Sarcoma, a

herpes virus-associated cancer. Many HIV/AIDS patients suffer from Kaposi’s, presently treated intravenously with resultant side effects (see article page 20).

Elaine Liu worked with Alexandre Steiner, Pharm.D., Ph.D., to research what happens with a shift from fever to hypothermia during Systemic Inflammatory Response Syndrome, which can lead to multiple organ failure and death.

Fourth-year student Neil Mandalaywala continued work he had done during past summers on Vitamin D-Up Regulated Protein. This time he studied the role of VDUP-1 in tumor growth, angiogenesis and metastasis at the Pharmaceutical Research Institute alongside Shaker Mousa, Ph.D., MBA. Anjoli Punjabi and mentor Arnold Johnson, Ph.D., did research at the V.A. Medical Center in Albany on preventing septic shock as it relates to the lungs, in particular studying the role of tumor necrosis factor.

For the third summer in a row, Alexandra Rehfuss ’09, who will earn her B.S. in Pharmaceutical Sciences in May, focused her work with Robert Levin, Ph.D., on the treatment of interstitial cystitis and incontinence in women.

Lastly, Peter Youssef presented on his work with Martha Hass, Ph.D. Peter used his background in chemistry and developed a project to analyze phospholipids not just qualitatively but, for the first time, quantitatively.

Two ACPHS students, Tasmina Hydery ’10 and Alex Villanueva ’09, have been awarded American Foundation for Pharmacy Education (AFPE) “Gateway to Research” Scholarships to conduct research with Department of Pharmaceutical Sciences faculty for the 2008–09 academic year. Considering that only 15 awards were given by AFPE nationwide, the fact that two were granted to ACPHS students speaks highly of the caliber of research being done by these students in conjunction with their faculty mentors.

Tasmina is working with mentor Robert Levin, Ph.D. on a project entitled “Mechanism of the protective effect of coenzyme Q10 and alpha lipoic acid on obstructive urinary bladder dysfunction.

According to Dr. Levin, more than 60 percent of all men over the age of 50 will develop weak bladders as the result of an enlarged prostate, which causes reduced blood flow to the bladder and the release of free radicals that damage bladder muscle. Working with rabbits, Tasmina’s research will try to determine if specific antioxidants will prevent the development of weak bladders.

Alex has conducted research with Carlos Feleder, Ph.D., on elucidating the role of endocannabinoids in septic shock, which results in an estimated 200,000 deaths each year in the U.S. alone. Together they have discovered that administration of Rimonabant, a cannabinoid receptor antagonist, prior to administration of shock-inducing lipopolysaccharide (LPS) blocks shock-related hypotension.

Gateway to Research Scholarships provide outstanding Pharm.D. students and undergraduates in other science disciplines with support for a faculty supervised research experience. The program strives to attract the most talented students to graduate study in the pharmaceutical sciences by offering a rewarding undergraduate research experience that includes a $4,000 stipend and $1,000 for supplies.

For more information on the program, visit http://www.afpenet.org/

PrezRepVF

4/15/09

1:41 PM

Page 25

ACPHS 2008

// 25

Reservation Rotation Philip Lubanski ’09 Gains Experience in the Navajo Nation

Native American studies are not generally the first thing that comes to mind when thinking of ACPHS. But a series of electives taken through the Department of Arts and Sciences at the College were influential in Philip Lubanski’s decision to undertake an ambulatory care rotation in the Navajo Nation.

Phil spent a month with the tribe last summer at the Chinle Comprehensive Health Care Facility (CCHCF) located on the Navajo Indian Reservation in Arizona. Before embarking on his Advanced Pharmacy Practice Experience, the sixth-year Pharm.D. student took nearly all of the College’s courses on Native Americans, including one on Southwestern American Indians.

“These electives are what really sparked my interest in the rotation,” Phil explains. “Learning about the culture and actually living on the reservation are two totally different things, but Dr. [J. Daniel] d’Oney was very helpful in teaching me about Navajo traditions and important landmarks located near Chinle.”

The reservation, in the northeast corner of Arizona, encompasses the famed Canyon de Chelly, site of

ancient Native American ruins and now home to a living community of Navajo people.

“The Navajo really pride themselves on holding on to their culture and language,” says Phil.

“Many of the patients I encountered there spoke little or no English. For others, English was their second language.”

Phil was assigned to the CCHCF, a part of the Navajo Area Indian Health Service (IHS). A 60bed hospital, the facility serves as a health care hub for the region. The pharmacy rotation has accommodated a steady stream of ACPHS students, says Director of Experiential Education Laurie Briceland, Pharm.D., who was instrumental in establishing the practice site about 15 years ago.

“There are no ’traditional’ pharmacies on the reservation, just a grocery store that sells some common over-the-counter medications,” Phil says. “The only pharmacies are in the IHS hospitals and outpatient clinics. Most Navajo people get all of their medications from the hospital, including OTC medications like non-steroidal anti-inflammatory drugs (NSAIDs).”

Phil’s primary responsibility at the clinic was counseling, predominantly in the areas of NSAIDs, antibiotic use and diabetes, the most common medical problem faced by the Navajo people.

“Diabetes is a huge issue on the reservation and one that the IHS is working very hard to get under control,” Phil explains. “By controlling patients’ blood sugars, we can prevent further complications down the road, such as neuropathies, blindness and nephropathy.”

“Counseling really allowed a lot of interaction with the Navajo people,” he adds. “Many folks don’t have televisions, cable, internet access or even newspapers, so the counseling they get at the clinic is really all that many of them know about their medications.”

There were several cultural differences Phil had to be aware of when working with the tribe.

“The Navajo don’t speak of the deceased, so [when taking a medical history] it is important to look at a patient’s chart before asking about their parents or grandparents, to make sure that they haven’t passed away.”

He also had to be careful when explaining the side effects of medications as many Navajo believe that stating that something may happen in the future will cause the event to occur.

The hospital itself also differs from its off-reservation counterparts. The CCHCF employs traditional healers for patients who request a Navajo ceremony, which is then performed in a traditional Navajo building or ’hogan’ that is located right on the hospital grounds.

“It was pretty neat trying to convey medication information across cultural and educational barriers. At times it was a bit challenging, but I have not experienced a reward professionally that rivals the feeling of knowing that you have just taught someone something about their medications or disease state that they couldn’t have gotten anywhere else.”

The Navajo Indian Reservation encompasses Canyon de Chelly.

PrezRepVF

4/15/09

1:41 PM

Page 26

Financials BALANCE SHEET

ASSETS Cash and cash equivalents Investments Other assets Accounts receivable—students Receivables—government entities Other receivables Pledges receivable Student loans receivable Agency funds Deposits with bond trustees Property, plant & equipment—Net Total assets LIABILITIES AND NET ASSETS Liabilities Line of credit Accounts payable and accrued liabilities Deferred income and deposits U.S. government grants refundable Bonds payable Capital lease obligation Expected post retirement benefit obligation Deposits held in custody for others Total liabilities Net Assets UNRESTRICTED For current operations Funds functioning as an endowment Designated for plant capital Plant fund Total unrestricted net assets TEMPORARILY RESTRICTED Unexpended funds received for restricted purposes Total temporarily restricted net assets PERMANENTLY RESTRICTED Endowment funds O’Brien Loan Fund Total permanently restricted net assets Total net assets Total liabilities and net assets

$

$

$

$

$

14,801,492 10,586,516 3,389,866 425,919 1,583,276 539,782 1,145,057 2,391,585 200,958 1,552,475 45,602,328 82,219,254

0 895,967 8,539,234 2,133,125 29,700,776 0 830,251 200,958 42,300,311

$

2,329,399 4,602,824 7,000,000 19,585,915 33,518,138

$ $

1,768,115 1,768,115

$

4,598,365 34,325 4,632,690 39,918,943 82,219,254

$

PrezRepVF

4/23/09

2:24 PM

Page 27

ACPHS 2008

// 27

REVENUES

Auxiliary Enterprises 8.80%

Gifts and Pledges 4.86% Investment Income 0.93% Postgraduate Education 0.30% Other Sources 1.65%

Revenues Student Tuition an Revenues Government Cont Student Tuition an Gifts and Pledges Government Cont Investment incom Gifts and Pledges Postgraduate Edu Investment incom Other SourcesEdu 1.6 Postgraduate Auxiliary Enterpri Other Sources 1.6 100.00% Enterpris Auxiliary 100.00%

Government Contracts and Grants 8.43%

Student Tuition and Fees 75.03%

EXPENSES

Expenses General Administr Expenses Research 10 General Administr Student Financial Research 10 Physical Financial Plant 26 Student Institutional Adva Physical Plant 26 Postgraduate Edu Institutional Advan Investment losses Postgraduate Edu Instruction/Stude Investment losses 100.00% Instruction/Studen 100.00%

Student Financial Aid 1.46%

Research 10.86%

Physical Plant 26.68%

Institutional Advancement 3.94%

Postgraduate Education 0.44% Investment Losses 1.76%

Instruction/Student Services 37.38%

General Administration 17.48%

PrezRepVF

4/15/09

1:41 PM

Page 28

S C H O L A R LY A C T I V I T Y

PrezRepVF

4/15/09

1:41 PM

Page 29

ACPHS 2008

// 29

Pharmaceutical Research Institute PUBLICATIONS Chu F, Chou P, Mirkin BL, Mousa SA and Rebbaa A. Cellular conditioning with Trichostatin A enhances the anti-stress response through upregulation of HDAC4 and down-regulation of the IGF/AKT pathway. Aging Cell, May 16, 2008 [Epub ahead of print].

Al Sayegh FA Dr, Almahmeed W, Marashi M, Bahr A, Mahdi HA, Bakir S, Alhumood S, Farhan MA and Mousa S. Global risk profile verification in patients with venous thromboembolism in Arabian Gulf Countries. Clinical and Applied Thrombosis/Hemostasis, April 8, 2008 [Epub ahead of print].

Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis, April 4, 2008 [Epub ahead of print].

Fares RR, Lansing LS, Gallati CA and Mousa SA. Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: Clinical evidence for and against the combination. Expert Opinion on Pharmacotherapy 9(3):377-86, February 2008.

Alsayegh F, Fakeir A, Alhumood S, Abdumalek K, Matar H, Samaul I, Nampoory N, Kabalawi H and Mousa S. Use of recombinant activated factor VII to arrest uncontrolled bleeding: A case series.

Clinical and Applied Thrombosis/Hemostasis, Dec 26, 2007 [Epub ahead of print].

Mousa SA. Cell adhesion molecules: potential therapeutic & diagnostic implications. Molecular Biotechnology 38(1):33-40, January 2008.

Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, Huebert N, Bursell SE, Clermont AC, Grant MB, Shaw LC, Mousa SA, Galemmo RA Jr, Johnson DL, Maryanoff BE and Damiano BP. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. The Journal of Pharmacology and Experimental Therapeutics. 324 (3):894-901, March 2008.

Mousa SA, Bergh JJ, Dier E, Rebbaa A, O’Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY and Davis PJ. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11(2):183-90, 2008.

Mousa SA, Zhang F, Aljada A, Chaturvedi S, Takieddin M, Zhang H, Chi L, Castelli MC, Friedman K, Goldberg MM and Linhardt RJ. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. Journal of Clinical Pharmacology 47(12):1508-20, December 2007.

Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, Robson T and Francis JL. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Seminars in Thrombosis and Hemostasis 33(7):643-52, October 2007.

Mousa SA, Bharali DJ and Armstrong D. From nutraceuticals to pharmaceuticals to nanopharmaceuticals: A case study in angiogenesis modulation during oxidative stress. Molecular Biotechnology 37(1):72-80, September 2007.

Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, Alsaigh M, Alalfi A, Alamin M, Gadi A and Mousa SA. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial.

Thrombosis and Haemostasis 98(2):392-6, August 2007.

Bharali DJ, Mousa SA and Thanavala Y. Micro- and nanoparticle-based vaccines for hepatitis B. Advances in Experimental Medicine and Biology 601:415-21, 2007.

Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Seminars in Thrombosis and Hemostasis 33(5):524–33, July 2007.

PROJECT: Kininogen in ocular angiogenesismediated disorders SPONSOR: Vascular Vision Pharmaceuticals Co./NIH (Eye Institute and Cancer Institute) TOTAL GRANT: $100,000 PROJECT PERIOD: 12/06–09/07 PROJECT: Wound healing and haemostatic treatment using novel pharmaceutical nanopolymer or nanoparticles formulation of thyroid hormone T4 analogs SPONSOR: Charitable Leadership Foundation Medical Technology Acceleration Program TOTAL GRANT: $306,900

Powell JA Jr. and Mousa SA. Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis. Journal of Cellular Biochemistry 102(2):412–20, October 2007.

PROJECT PERIOD: 4/06–12/07

Ovsag K, Hydery S and Mousa SA. Preferred drug lists: Potential impact on health care economics.

Vascular Health and Risk Management 4(2):403–413, 2008.

SPONSOR: Vascular Vision Pharmaceuticals Co./NIH (Eye Institute and Cancer Institute)

PROJECT: Tissue factor/VIIa modulation in ocular angiogenesis

TOTAL GRANT: $100,000 PROJECT PERIOD: 6/06–11/07

GRANTS AND CONTRACTS PROJECT: Evaluate the pharmacological activity of SelectX compounds in a panel of in vitro assays

PROJECT: Cellular and molecular mechanisms of TPH in the modulation of complement activation and inflammation

SPONSOR: SelectX

SPONSOR: Othera Pharmaceuticals, Inc.

TOTAL GRANT: $15,360

TOTAL GRANT: $54,000

PROJECT PERIOD: 1/07–1/08

PROJECT PERIOD: 3/06–11/07

PROJECT: Role of 1, 6 Anhydo in Enoxaparin fractions in the modulation of endothelial tissue factor pathway inhibitor SPONSOR: Aventis TOTAL GRANT: $100,000 PROJECT PERIOD: 6/06–09/07 PROJECT: Evaluations of anti-angiogenesis thyroid hormone antagonists in cancer models SPONSOR: Charitable Leadership Foundation Medical Technology Acceleration Program TOTAL GRANT: $231,250

PROJECT: Cellular and molecular mechanisms of TPH in the modulation of complement activation and inflammation (amendment) SPONSOR: Othera Pharmaceuticals, Inc. TOTAL GRANT: $48,000 PROJECT PERIOD: 3/06–12/07 PROJECT: Neuronal protective effects and mechanisms of Othera’s OT551 nanoparticles SPONSOR: Othera Pharmaceuticals, Inc. TOTAL GRANT: $56,000 PROJECT PERIOD: 9/06–12/07

PROJECT PERIOD: 9/05–9/07 PROJECT: Assay of iron and sucrose in samples SPONSOR: Genix Pharma, Ltd. TOTAL GRANT: $18,964 PROJECT PERIOD: 12/31/06–12/07 PROJECT: Generation of tetrac conjugate polymers, physiochemical characterization, and initial stability assessment SPONSOR: Charitable Leadership Foundation Medical Technology Acceleration Program

PROJECT: Retinal neovascularization in infant mice in ROP SPONSOR: Othera Pharmaceuticals, Inc TOTAL GRANT: $14,400 PROJECT PERIOD: 11/06–12/07 PROJECT: The effect of OT551 on nuclear factorkB pathway activation SPONSOR: Othera Pharmaceuticals, Inc TOTAL GRANT: $91,800 PROJECT PERIOD: 12/06–12/07

TOTAL GRANT: $125,000 PROJECT PERIOD: 1/06–12/07

PROJECT: Funding for Postdoctoral fellow SPONSOR: Othera Pharmaceuticals, Inc

PROJECT: Anti-angiogenesis efficacies of TransMolecular lead TM601 SPONSOR: TransMolecular, Inc. TOTAL GRANT: $27,300 PROJECT PERIOD: 9/06–12/07

TOTAL GRANT: $43,802 per year PROJECT PERIOD: 03/07–03/09

PrezRepVF

4/15/09

1:41 PM

Page 30

PROJECT: Reversal of chemotherapy resistance with Othera analogs SPONSOR: Othera Pharmaceuticals, Inc TOTAL GRANT: $81,600 PROJECT PERIOD: 12/06–12/07

PROJECT: Role of Pentasaccharide Fondaparinux versus low molecular weight Heparin in wound healing (Amended to study role in cancer-associated thrombosis) SPONSOR: Sanofi-Aventis and GlaxoSmithKline TOTAL GRANT: $35,700

PROJECT: Anti-angiogenesis efficacy of TM610 against various pro-angiogenesis factors SPONSOR: TransMolecular, Inc. TOTAL GRANT: $18,150 DATES: 6/08–12/08

PROJECT PERIOD: 07/07–06/08 PROJECT: Assay of tetrac in plasma samples SPONSOR: Charitable Leadership Foundation Medical Technology Acceleration Program TOTAL GRANT: $79,350 PROJECT PERIOD: 12/06–11/07

PROJECT: Experimental models for testing novel targets for pancreatic cancer cell invasion PROJECT: Role of Heparin and Heparin derivatives beyond anticoagulation SPONSOR: Sanofi-Aventis TOTAL GRANT: $100,000

SPONSOR: National Institutes of Health TOTAL GRANT: $368,445 DATES: 4/08–3/10

DATES: 9/04–9/07 PROJECT: In vitro evaluation of platelet activation by the test article in human blood SPONSOR: Merck & Co., Inc. TOTAL GRANT: $23,750 PROJECT PERIOD: 2/07–2/08

PROJECT: Role of Cathepsin inhibitors in angiogenesis and chemoresistance

PROJECT: Evaluation of the anti-angiogenesis efficacy of Tetrac versus two different Tetrac nanoformulations

SPONSOR: NSF-US-EGYPT Exchange Program

SPONSOR: Charitable Leadership Foundation Medical Technology Acceleration Program

TOTAL GRANT: $24,950

TOTAL GRANT: $11,220

DATES: 9/07–8/09

DATES: 6/3/2008–6/13/2008

PROJECT: Potent lipid mediators and ischemic heart diseases (Upstate New York Translational Research Network—University of Rochester, Cornell University and PRI at ACPHS)

ABSTRACTS/PRESENTATIONS

PROJECT: Anti-angiogenesis and Anti-cancer efficacies and mechanisms of TM601 SPONSOR: Transmolecular, Inc. TOTAL GRANT: $66,700 PROJECT PERIOD: 2/07–11/07

XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland, July 2007 (6 abstracts)

SPONSOR: Foundation for Healthy Living PROJECT: PK/PD of OT304 and OT551 in rat Carrageenan-induced paw edema model

TOTAL GRANT: $14,309

KeyStone Symposia, Breckinridge, Colorado, 2008 (1 abstract)

SPONSOR: Othera Pharmaceuticals, Inc TOTAL GRANT: $10,080 PROJECT PERIOD: 2/07–8/07

PROJECT: Othera XVII OT 304 effect on growth of doxorubicin resistant MCF7 cells in nude mice SPONSOR: Othera Pharmaceuticals, Inc.

PROJECT: PK and PD evaluations of Othera’s lead compounds in a Murine model of Endotoxininduced Cytokine release SPONSOR: Othera Pharmaceuticals, Inc TOTAL GRANT: $54,060 PROJECT PERIOD: 2/07–8/07

SPONSOR: Othera Pharmaceuticals, Inc TOTAL GRANT: $37,800 PROJECT PERIOD: 2/07–8/07

DATES: 10/07–3/08

7th International Haemostasis, Saudi Arabia, May 2008 (2 abstracts)

PROJECT: Othera XVIII-Efficacy of OT-304 in mice Xenograft models using drug-sensitive cancer cell lines

American Society of Clinical Oncology, Chicago, Ill., May 2008 (1 abstract)

TOTAL GRANT: $49,500 DATES: 12/08–06/08 PROJECT: In Vitro study on extracorporeal filtration system to remove oxaliplatin from bovine blood SPONSOR: Delcath Systems

PROJECT: Cancer and drug associated thrombosis

TOTAL GRANT: $155,650 DATES: 12/07–11/08

SPONSOR: Othera Pharmaceuticals, Inc TOTAL GRANT: $78,900 PROJECT PERIOD: 1/07–11/07 PROJECT: OT551 and OT304 nanoparticle formulation: Synthesis and characterization.

SPONSOR: Othera Pharmaceuticals, Inc

PROJECT: Othera XVIIII-efficacy of OT-304 on growth of matrigel implanted pancreatic, ovarian and glioma cancer cells in nude mice SPONSOR: Othera Pharmaceuticals, Inc. TOTAL GRANT: $49,500 DATES: 02/08–09/08

TOTAL GRANT: $66,000 PROJECT PERIOD: 6/07–5/08 PROJECT: Enhancing the efficacy of chemotherapeutic breast cancer treatment with non-anticoagulant heparin SPONSOR: U.S. Dept. of Defense Breast Cancer Research Program TOTAL GRANT: $377,620 PROJECT PERIOD: 4/07–3/09

Association for Research in Vision and Opthamology, Fort Lauderdale, Fla., April 2008 (3 abstracts)

TOTAL GRANT: $49,500

SPONSOR: Othera Pharmaceuticals, Inc. PROJECT: Evaluation of Othera’s lead Compounds in Murine model of Oxazoloneinduced ear edema

American Cancer Association, San Diego, Calif., 2008 (3 abstracts)

DATES: 9/07–8/08

PROJECT: Assay of over-sulfated Chondroitin Sulfate in Heparin samples SPONSOR: Medtronic Inc. TOTAL GRANT: $50,160 DATES: 4/08–5/08

American Thyroid Society Meeting, June 2008 (1 abstract)

PrezRepVF

4/15/09

1:41 PM

Page 31

ACPHS 2008

// 31

Pharmacy Practice Machaon Bonafede

Lodise TP and McKinnon PS. Outcomes and economic considerations with serious infections due to Methicillin resistant Staphylococcus aureus.

Pharmacotherapy 27(7):1001–12, July 2007.

Bonafede M, Dick A, Noyes K, Klein JD and Brown T. The effect of acupuncture utilization on healthcare utilization. Medical Care 46(1):41-8, January 2008.

Miller CD, El-Kholi R, Faragon J and Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.

Pharmacotherapy 27(10)1379–1386, 2007.

PUBLICATIONS

Nicole M. Stack Lodise Stack NM and Zillich AJ. Implementation of inpatient and outpatient tobacco cessation programs.

American Journal of Health-system Pharmacy 64: 2074-2079, October 2007.

Thomas P. Lodise Lodise TP, Pypstra R, Kahn JB, Murty BP, Kimko HC, Bush K, Noel G and Drusano GL. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrobial Agents and Chemotherapy 51:2378-2387, 2007.

Lodise TP, Miller CD, Patel N, Graves J and McNutt LA. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for carbapenem resistance.

Infection Control and Hospital Epidemiology 28(8):959–65, August 2007.

McGregor JC, Rich SA, Harris AD, Perencevich EN, Osih R, Lodise TP, Miller RR and Furuno JP. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clinical Infectious Diseases 45(3):329–37, August 2007.

Lodise TP, Kwa A, Cosler LE, Gupta R and Smith RP. Comparison of β-lactam and macrolide combination therapy vs. fluoroquinolone monotherapy in hospitalized Veteran Affairs’ patients with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy, August 2007 [Epub ahead of print].

Lodise TP, Kinzig-Schippers M, Drusano GL, Loos U, Vogel F, Bulitta J, Hinder M and Sörgel F. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrobial Agents and Chemotherapy 52(6):1945-51, June 2008.

Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN and Sörgel F. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: Results of population pharmacokinetic modeling and Monte Carlo Simulation. Journal Antimicrobial Chemotherapy 60:1038–44, November 2007.

Lodise TP, Patel N, Graves J, Kwa A, Furuno JP, Graffunder E, Lomaestro BM and McGregor JC. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: The impact of delayed appropriate antibiotic selection. Antimicrobial Agents and Chemotherapy 51(10):3510–5, October 2007.

Lodise TP, McKinnon PS, Levine DP and Rybak MJ. Impact of empirical therapy selection on outcomes of intravenous drug users with Methicillin susceptible Staphylococcus aureus infective endocarditis. Antimicrobial Agents and Chemotherapy 51(10):3731-3, October 2007.

Lodise TP, Nau R, Kinzig M, Jones RN and Sörgel F. Comparison of the probability of target attainment between Ceftriaxone and Cefepime in the cerebrospinal fluid and plasma against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease 58(4):445–52, August 2007.

Lodise TP, Gotfried M, Barriere S and Drusano GL. Telavancin penetration into human epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo Simulation.

Antimicrobial Agents and Chemotherapy, April 2008 [Epub ahead of print].

Lodise TP, Lomaestro BM, Graves J and Drusano GL. Larger Vancomycin doses are associated with an increased incidence of nephrotoxicity.

Antimicrobial Agents and Chemotherapy 52(4); 1330–6, April 2008.

Margaret Malone Malone M. The obesity pandemic: How did we get here? The Annals of Pharmacotherapy 41:1497–8, 2007.

Cerulli J and Malone M. Women’s health promotion within a community advanced pharmacy practice experience. American Journal of Pharmaceutical Education 72(2):Article 25, 2008.

Alger-Mayer S, Polimeni J and Malone M. Preoperative weight loss as a predictor of long term success following Roux-en-Y gastric bypass.

Obesity Surgery, April 2008 [Epub ahead of print].

Alger-Mayer S. Rosati C, Polimeni J and Malone M. Pre-operative binge eating status and gastric bypass surgery. Obesity Surgery, May 2008 [Epub ahead of print].

John M. Polimeni Mohr JF, Peymann PJ, Troxell E, Lodise TP and Ostrosky-Zeichner L. Risk factors for hyperglycemia in hospitalized adults receiving Gatifloxacin: A retrospective, nested case-controlled analysis. Clinical Therapeutics 30(1):152–7, January 2008.

Bhat SV, Peleg AY, Lodise TP, Shutt KA, Capitano B, Potoski BA and Paterson DL. Failure of current cefepime breakpoints to predict clinical outcomes from Gram negative bacteremia. Antimicrobial Agents and Chemotherapy 51(12):4390–5, December 2007.

Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR and Jones RN. Pharmacokinetic and pharmacodynamic profile of Ceftobiprole.

Diagnostic Microbiology and Infectious Diseases 61(1):96-102, May 2008.

Lodise TP and Neuhauser M. Community-associated Methicillin-resistant Staphylococcus aureus in Pharmacotherapy Self-Assessment Program, Sixth Edition, Infectious Diseases (Dunsworth T, Richardson M, Chant C, Cheng JWM, Chessman KH, Hume AL, et al, eds.), Lenexa, Kan.: American College of Clinical Pharmacy, 37–54, 2008.

Lodise TP, Lomaestro BM and Drusano GL. Practical Application of pharmacodynamic principles to optimize therapy and treat resistant organisms: A focus on Beta-Lactam antibiotics in Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures (Owens RC and Lautenbach E, eds.), New York, N.Y.: Informa Healthcare USA, Inc., 317–335, 2008.

McKinnon PS and Lodise TP. Outcomes and cost considerations with MRSA infections. in MRSA (Weigelt J, ed.), New York, N.Y.: Informa Healthcare USA, Inc., 189–211, 2008.

Patel N, McNutt LA and Lodise TP. The relationship between varying prior antibiotic exposure definitions and piperacillin/tazobactam resistance among patients with Pseudomonas aeruginosa respiratory tract infections. Antimicrobial Agents and Chemotherapy, June 2008 [Epub ahead of print].

Teresa J. Lubowski Lubowski TJ, Cronin LM, Pavelka R., BriscoeDwyer L. and Hamilton RA. A medication reconciliation project conducted by Pharm. D. students during an APPE in a multi-site health system.

American Journal of Pharmaceutical Education 71 (5): Article 94, 2007.

Polimeni JM. Assessment of the economics curriculum at a college of pharmacy. Journal of College Teaching and Learning 4(10):47–56, October 2007.

Polimeni JM and Polimeni RI. Energy consumption in transitional economies (Part I): Jevons’ Paradox for Romania, Bulgaria, Hungary and Poland.

Romanian Journal of Economic Forecasting 4(3):63-80, September 2007.

Polimeni RI and Polimeni JM. Multi-scale integrated analysis of societal metabolism and Jevons’ Paradox for Romania, Bulgaria, Hungary and Poland (Part II). Romanian Journal of Economic Forecasting 4(4):61–76, December 2007.

Onyeiwu S, Polimeni RI and Polimeni JM. Distributional impact of globalization-induced migration: Evidence from a Nigerian Village.

WIDER Research Paper 66, October 2007.

Onyeiwu S, Polimeni RI and Polimeni JM. Distributional impact of globalization-induced migration: Evidence from a Nigerian Village.

African Development Review 20(1):115–34, April 2008.

Polimeni JM. Jevons’ Paradox: A case study of China. International Journal of Interdisciplinary Social Sciences 2(2): 383–394, 2007.

Polimeni RI and Polimeni JM. Structural adjustment and the Igbo extended family. International Journal of the Humanities 5(4):77-82, 2007.

Polimeni RI and Polimeni JM. Multi-scale integrated analysis of societal metabolism: The case of Romania. International Journal of Interdisciplinary Social Sciences 2(2):41–51, 2007.

Polimeni JM. Protecting the global food supply from a terrorist attack. International Journal of the Humanities 5(4):71–75, 2007.

Polimeni JM. Assessment of the economics curriculum at a college of pharmacy. Journal of College Teaching & Learning, 4(10):47–56, 2007.

Polimeni JM. Jevons’ Paradox and the economic implications for Europe. International Business and Economics Research Journal, 6(10):109–119, 2007.

Polimeni JM, Mayumi K, Giampietro M and Alcott B. The Jevons’ Paradox: The Myth of Resource Efficiency Improvements. London, U.K: Earthscan Publications, Ltd., January 2008.

PrezRepVF

4/15/09

1:41 PM

Page 32

ABSTRACTS/PRESENTATIONS Machaon Bondafede Guilbert T, Schatz M, Davis EA, Tomaszewski KJ and Bonafede M. Health care utilization is higher among patients whose asthma is not well-controlled: Evidence from a large longitudinal cohort.

American Academy of Allergy Asthma and Immunology Annual Meeting, Philadelphia, Pa., March 2008.

Garris C, Schatz M, Guilbert T, Davis EA, Bonus T and Bonafede M. Asthma control is predictive of health-related quality of life: Survey using the Asthma Control Test™ and Childhood Asthma Control Test™. American Academy of Allergy Asthma and Immunology Annual Meeting, Philadelphia, Pa., March 2008.

Garrison GD. Cardiovascular risk factors.

Continuing Education program, Pharmacists Society of the State of New York Mid-winter Conference, Saratoga Springs, N.Y., January 2008.

Garrison GD. Ties that bind: Professional relationships with pharmaceutical industry. Pharmacy Practice Institute, Albany College of Pharmacy, Albany, N.Y., March 2008.

Garrison GD. Ties that bind: Professional relationships with industry. St. Peters Hospital Medical Grand Rounds, Albany, N.Y., April 2008.

Garrison GD. Keynote address. Beta Theta chapter induction, Rho Chi Pharmacy Honor Society, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University— Brooklyn Campus,. Brooklyn, N.Y., May 2008.

Nicole M. Lodise Michael R. Brodeur Brodeur MR. Medications and older adults with a focus on dysphagia. New York State Disability Services and Organizations, Syracuse N.Y., September 2007.

Brodeur MR. Anticholinergic medications and older adults. Continuing Education Program, Albany College of Pharmacy, Albany, N.Y., September 2007.

Brodeur MR. Diphenhydramine and tetracaine.

Colonie Emergency Medical Services, Albany, N.Y., September 2007.

Lodise NM. Tobacco cessation in the inpatient setting. Greater New York Hospital Association, East Elmhurst, N.Y.,October 2007.

Lodise NM. Nicotine dependence and treatment: A look at the myths and facts. Addiction Medicine Institute, Albany Medical Center, Albany, N.Y., November 2007.

Lodise NM. Cervical cancer and the HPV vaccine.

Pharmacy in the News Continuing Education program, Albany College of Pharmacy, Albany, N.Y., November 2007.

Miller C, El-Kholi R, Lodise TP and Fish D. Virologic and immunologic efficacy of Didanosine/Tenofovir as a NRTI backbone within PI-based HAART. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., September 2007.

Patel N, Graffunder E, Evans A, Helmecke M, Stellrecht K and Lodise TP. Relationship between hVISA and outcomes among patients with MRSA bloodstream infections treated with Vancomycin.

18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain. April 2008.

Patel N, Graffunder E, Evans A, Helmecke M, Stellrecht K and Lodise TP. Predictors of hVISA among patients with MRSA bacteremia. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain. April 2008.

Patel N and Lodise TP. Predictors of piperacillinresistant Pseudomonas aeruginosa among patients with respiratory tract infections: The predictive value of varying exposure definitions and the risk of multiple prior antibiotic exposures.18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain. April 2008.

Lodise TP. Continuous and short-term infusion strategies. Making a Difference in Infectious Diseases Pharmacotherapy Annual Conference, Orlando, Fla., May 2008.

Lodise NM. Tobacco cessation for the busy clinician. Albany Medical Center OB/GYN Grand Rounds, Albany, N.Y., November 2007.

Lodise T. Resistant gram-negative infections: New treatment approaches—Improving the outcome with PK/PD. Making a Difference in Infectious Diseases Pharmacotherapy Annual Conference, Orlando, Fla., May 2008.

Lodise NM. How to incorporate tobacco cessation into a busy setting. New York State Council of Health-system Pharmacists Winter Conference, Killington, Vt., January 2008.

Lodise T. Treatment of MRSA: New and improved versus old and reliable. Continuing Education program, Albany College of Pharmacy, Albany, N.Y., April 2008.

Brodeur MR and Saffel D. Proton pump inhibitors: Point, counterpoint. American Medical Directors Association, Salt Lake City, Utah, March 2008.

Thomas P. Lodise

Lodise T. MRSA Update. Continuing Education program, Albany College of Pharmacy, Albany, N.Y., February 2008.

Jennifer Cerulli

Lodise TP, Lomaestro BM, Graves J and Drusano GL. Higher empirical Vancomycin dosing is associated with increased nephrotoxicity. 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, Calif., October 2007.

Brodeur MR and Pannenton K. Anticholinergic medications. Island Peer Review Organization (IPRO) Teleconference, New York State, November 2007.

Brodeur MR. Naloxone. Colonie Emergency Medical Services, Albany, N.Y., January 2008.

Cerulli J. Community pharmacy practice initiative to support the identification and education of people with Chronic Obstructive Pulmonary Disease. American Pharmacists Association 2008 Annual Meeting and Exposition, San Diego, Calif., March 2008.

Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M and Stellrecht K. Predictors of Vancomycin treatment failure among patients with MRSA bacteremia. 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, Calif., October 2007.

Angela C. Dominelli Bruce SP, Schwartz A and Dominelli A. Survey of curricular changes. Annual Meeting of the American Association of Colleges of Pharmacy, Orlando, Fla., July 2007.

Gina D. Garrison Garrison GD, Strang AF, Rivers S and Lubowski TJ. A pharmacy student based coronary heart disease (CHD) risk assessment service in the ambulatory care setting: Patient and student outcomes.

American Association of Colleges of Pharmacy Annual Meeting, Orlando, Fla., July 2007.

Garrison GD. Pharmaceutical industry influence at an academic medical center. Department of Medicine Grand Rounds, Albany Medical Center, Albany, N.Y., September 2007.

Garrison GD. Dyknow educational technology use in the large or small classroom: Sharing the experience. Fall 2007 Capital District Educational Technology Group Conference, Albany College of Pharmacy, Albany, N.Y., October 2007.

Lodise TP, Lomaestro B, Kwa A and Drusano GL. Pharmacodynamics of extended infusion Piperacillin/Tazobactam against Pseudomonas aeruginosa. 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, Calif., October 2007.

Helmecke M, Graves J, Evans A, Graffunder E, Stellrecht K and Lodise TP. Predictors of Vancomycin MIC 2 mg/L among patients with MRSA bacteremia. 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, Calif., October 2007.

Drusano GL, Ambrose PG, Bhavnani SM, Lodise TP, Rubino CM, Forrest A, Louie A and Rodvold KA. Vancomycin dose recommendations for hospital-, ventilator- or health care- associated pneumonia and the attainment of Vancomycin through concentrations of 15-20 mg/L: Cognitive Dissonance. 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, Calif., October 2007.

Teresa J. Lubowski Lubowski TJ and Cerulli J. Quality assurance program for pharmacy practice experiences using CAPE-based capabilities checklists. American Association of Colleges of Pharmacy, Orlando, Fla., July 2007.

Margaret Malone Malone M. Altered drug disposition after bariatric surgery. Treatment options for obesity: Focus session on bariatric surgery. American College of Clinical Pharmacy Spring Practice and Research Forum, Phoenix, Ariz., April 2008.

Macary W. Marciniak Marciniak MW and Malone D. National Immunization Awareness Month /APhA-ASP Operation Immunization, Schenectady Today— Wednesday Edition (live interview), August 2007 Marciniak MW. Patient-centered care to minimize cardiovascular risk: How to fit outcomes monitoring in the busy community pharmacy practice.

Continuing Education Program, Albany College of Pharmacy, Albany, NY, August 2007.

Marciniak MW and Davison L. American Pharmacists Month, Schenectady Today–Wednesday Edition (live interview), October 2007.

PrezRepVF

4/15/09

1:41 PM

Page 33

ACPHS 2008

Marciniak MW. Pharmacist and student pharmacist perceptions of the self-care championship.

Nonprescription Medicines Academy, Cincinnati, Ohio, October 2007.

Marciniak MW. Navigating through the pharmacy residency process, American Pharmacists Association—Academy of Student Pharmacists (APhA-ASP) Midyear Regional Meeting, Denver, Colo., October 2007.

Christopher D. Miller

Tanya Vadala

Miller CD. Antiretroviral therapy in 2007. Kinney Drug Regional Office, Syracuse, N.Y., September 2007.

Vadala T and Flynn A. NYS Board review. PSSNY, Saratoga Springs, N.Y., January 2008.

Miller C. Approach to salvage and treatmentexperienced patients with HIV. New York State Department of Corrections, Albany, N.Y., January 2008.

Marciniak MW. Progress report: Providing clinical pharmacy services in chain pharmacies. American College of Clinical Pharmacy Annual Meeting, Denver, Colo., October 2007.

Miller C. What’s bugging you? Influenza vaccine and therapy. Annual Pulmonary Update, Albany, N.Y., January 2008.

Marciniak MW. The role of pharmacist as immunizer. Nassau/Suffolk Adult Immunization Conference, Melville, N.Y., October 2007.

John M. Polimeni

Marciniak MW. Navigating through the pharmacy residency process, American Pharmacists Association - Academy of Student Pharmacists (APhA-ASP) Midyear Regional Meeting, Albany, N.Y., October 2007.

Marciniak MW. Pharmacists as immunizers. New York Chapter of the American College of Physicians Scope of Practice Forum, Syracuse, N.Y., October 2007.

// 33

GRANTS Leon E. Cosler PROJECT: Regional variation in cancer-care treatment and outcomes SPONSOR: ACP Scholarship of Discovery and Educational Excellence Grant

Polimeni JM. Analysis of medicinal drugs as groundwater pollutants and a possible solution.

Seminar of the School of Doctorate Studies in the Pharmacological Sciences, Department of Farmacology and Anestesiolgy, Universita’ Degli Studi di Padova, September 2007.

Polimeni JM. Institutions and organizations in the European agri-food systems: Economic and sociological approaches. Universita’ Degli Studi di Perugia, Facolta’ di Agraria, Perugia, Italy, September 2007.

CO-INVESTIGATORS: Sarah Scarpace, Machaon Bonafede and Steve Szebenyi TOTAL GRANT: $15,000 GRANT PERIOD: 2008–2009 Sara E. Dugan PROJECT: AACP Annual Meeting SPONSOR: 2008 Wal-Mart Annual Conference Scholarship Program CO-AWARDEE: Leona Blustein TOTAL GRANT: $1,000

Marciniak MW. Immunization and the pharmacist.

Albany College of Pharmacy Annual Law Day, Albany, N.Y., November 2007.

Marciniak MW and White L. American Pharmacists Association Pharmacy-based Immunization Delivery Certificate Training Program. Pharmacists Society of the State of New York Midwinter Conference, Saratoga Springs, N.Y., January 2008.

Marciniak MW. Medicare Modernization Act: OTCs to get through the gap. Virginia Pharmacists Association Mid-Year Conference, Charlottesville, Va., February 2008.

Marciniak MW. Pharmacists as immunizers: Testimony provided on avian influenza and the “Pharmacists as Immunizers” bill. New York City Council Committee on Health, New York, N.Y., February 2008.

Marciniak MW and Rothholz MC. Immunizations and the pharmacist. Institute for Continuing Education/1199 SEIU League Training and Upgrading Fund, New York, N.Y., March 2008.

Marciniak MW. Medication Therapy Management.

Press briefing for the release of Medication Therapy Management in Pharmacy Practice: Core Elements of an MTM Service Model Version 2.0, San Diego, Calif., March 2008.

Marciniak MW. Medication Therapy Management: New help for prescription med questions.

Television interview for San Diego NBC, San Diego, Calif., March 2008.

Marciniak MW. Pharmacists as immunizers.

Television interview broadcast to Assemblywoman Amy Paulin’s 88th Assembly District, Westchester, N.Y., March 2008.

Marciniak MW. Pharmacists administering influenza and pneumococcal vaccines to adults in New York State. Roundtable discussion sponsored by Assemblyperson Deborah Glick, New York Academy of Medicine, New York, N.Y., May 2008.

Polimeni JM, Cosler LE, Chandrasekara R and Dobis M. A theoretical approach to reduce discarded pharmaceuticals in the environment.

Fourth International Conference on Environmental, Cultural, Economic and Social Sustainability, Universiti Malaysia, Terengganu, Malaysia, January 2008.

Polimeni J. Structural adjustment, economic development and vulnerability: Evidence from two Nigerian communities. 34th Annual Conference of the Eastern Economic Association, Boston, Mass., March 2008.

Polimeni J, Dobis M and Cosler LE. A cost-effectiveness analysis of a prescription and over-thecounter drug take-back program for New York State. 2007 Northeast Water Science Forum, Portland, Me., August 2007.

Polimeni J. Analysis of medicinal drugs as groundwater pollutants and a possible solution. Seminar of the School of Doctorate Studies in the Pharmacological Sciences, Universita’ Degli Studi di Padova, Padua, Italy, September 2007.

Aimee F. Strang Strang A, Bruce SP, Grabe D and Dominelli A. Mapping of pharmacotherapy outcomes: An assessment-based strategy. Annual Meeting of the American Association of Colleges of Pharmacy. Orlando, Fla., July 2007.

Sarah L. Scarpace Scarpace, SL. Ralox! The FDA approved it! SERMS for chemoprevention. Barbara DiLascia Lecture Series on Womens’ Health, Albany College of Pharmacy, Albany, N.Y., October 2007.

Scarpace SL. Board Certified Oncology Pharmacist presentation on Head/Neck Cancers.

Hematology Oncology Pharmacists Association/International Society of Oncology Pharmacy Practitioners 2008 Conference, Anaheim, Calif., June 2008.

Scarpace SL. Optimizing anti-emetics for chemotherapy-induced nausea/vomiting. ACP Continuing Education program: Annual Pharmacy Practice Institute, Albany, NY. March 2008.

Gina Garrison PROJECT: AACP Annual Meeting SPONSOR: 2008 Wal-Mart Annual Conference Scholarship Program CO-AWARDEE: Whitney Caron TOTAL GRANT: $1,000

PrezRepVF

4/15/09

1:41 PM

Page 34

Pharmaceutical Sciences PUBLICATIONS Richard E. Dearborn Jr. Mandalaywala NV, Chang S, Snyder RG, Levendusky MC, Voigt JM and Dearborn Jr. RE. The tumor suppressor vitamin D3 up-regulated protein 1 (VDUP1) functions downstream of REPO during Drosophila gliogenesis. Developmental Biology 315(2):489–504, March 2008.

Carlos Feleder Yilmaz MS, Millington WR and Feleder C. The preoptic anterior hypothalamic area mediates the hypotensive response induced by lipopolysaccharide in male rats. Shock 29(2):232–7, February 2008.

Pallares EM, Shmuckler J, Scacchi P, Feleder C and Cutrera RA. Effects of prenatal stress on motor performance and anxiety behavior in swiss mice. Physiology and Behavior 92:951–956, 2007.

Gail Goodman Snitkoff Goodman Snitkoff G. Common infectious diseases and immunization in Concepts in Immunology and Immunotherapeutics, 4th Edition (B. Smith, ed.), Bethesda, Md.: American Society of HealthSystem Pharmacists, 2008.

Goodman Snitkoff G. Immunology in Comprehensive Pharmacy Review, 7th Edition (L. Shargel, ed.), Philadelphia: Lippincott, Williams and Wilkins, 2008.

Goodman Snitkoff G. Microbiology in Comprehensive Pharmacy Review, 7th Edition.

(L. Shargel, ed.), Philadelphia: Lippincott, Williams and Wilkins, 2008.

Robert M. Levin Palmieri K, Mannikarottu AS, Chichester P, Kogan B, Leggett RE, Whitbeck C and Levin RM. The effects of cyclical estrogen on bladder and urethral structure and function. British Journal of Urology 99:171–176, 2007.

Whitbeck V, Chichester P, Sokol R and Levin RM. Role of nitric oxide in urinary bladder function: Effect of L-Arginine in the presence and absence of partial outlet obstructions. Urologia Internationalis 78:30–36, 2007.

Guven A, Whitbeck C, Chichester P, Leggett RE, Kogan BA, Mannikarottu AS and Levin RM. Effect of age on the response to short term partial bladder outlet obstruction in the rabbit. BJU International 100(4):930–934, October 2007.

Juan Y-S, Onal B, Broadway S, Cosgrove J, Leggett RE, Whitbeck C, De E, Sokol R and Levin RM. Effect of castration on male rabbit lower urinary tract tissue enzymes. Molecular and Cellular Biochemistry 301:227–233, 2007.

Lin W-Y, Rehfuss A, Whitbeck C, Juan W-S, Chichester P, Mannikarottu AS and Levin RM. Effect of Letrozole on female rabbit urinary bladder function. BJU International 100(6):1391–1395, December 2007.

Lin W-Y, Levin RM, Chichester P, Leggett RE, Juan Y-S, Johnson A, Neuman P, Whitbeck C, Guven A, Kogan BA and Mannikarottu AS. Effects of LArginine and L-NAME on chronic partial bladder outlet obstruction in the rabbit. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 293:2390-2399, 2007.

Guven A, Kalorin C, Onal B, Whitbeck C, Chichester P, Kogan BA, Levin RM and Mannikarottu AS. Novel biomarkers of bladder decompensation after partial bladder obstruction.

Neurourology and Urodynamics 26:1036–1042, 2007.

Juan Y, Lin W, Kalorin C, Kogan B, Levin RM and Mannikarottu AS. The effect of partial bladder outlet obstruction on carbonyl and nitrotyrosine distribution in rabbit bladder. Urology 70:1249–1253, 2007.

Onal B, Levin RM, Kogan BA, Guven A, Leggett RE and Mannikarottu AS. Novel alterations in superoxide dismutase and catalase activities in the female rabbit bladder subjected to hormonal manipulations. International Urology and Nephrology 39(4):1049-1054, 2008.

Chou EC, Whitbeck C, Herz J, Demopulos GA and Levin RM. The effect of intravesical ketoprofen on Acetylcholine-evoked urinary bladder contractility and detrusor overactivity in the anesthetized rabbit model. International Urology and Nephrology 39(4):1055–1059, 2007.

Chou EC, Whitbeck C, Borow A, Burden O, Mays P and Levin RM. The effect of intravesical ketoprofen on Ach-evoked urinary bladder contractility and hyperreflexia in the anesthetized rabbit model.

Arecht MM, Chichester P, Michel MC and Levin RM. Effect of short-term outlet obstruction on rat bladder nerve density and contractility.

Autonomic and Autacoid Pharmacology 27:47–53, 2007.

Lin WY, Guven A, Juan YS, Johnson A, Neuman P, Whitbeck C, Chichester P, Kogan B, Levin RM and Mannikarottu AS. Free radical damage as a biomarker of bladder dysfunction after partial outlet obstruction and reversal. BJU International 101:621–626, 2008.

Lin AD, Mannikarottu AS, Kogan BA, Whitbeck C, Leggett RE and Levin RM. Effect of bilateral invivo ischemia/reperfusion on the activities of superoxide dismutase and catalase: Response to a standardized grape suspension. Molecular and Cellular Biochemistry 296:11–16, 2007.

Levin RM, Juan Y-S, Whitbeck C., Perez-Martinez FC and Lin WY. The effect of Darifenacin on overactive bladder in female and male rabbits.

International Urology and Nephrology [EPub ahead of print, August 7, 2007].

Agartan CA, Leggett RE, Kogan BA and Levin RM. Effect of age on the response to in-vitro ischemia of the rabbit bladder. Urologia Internationalis 78:155–159, 2007.

Onal B, Levin RM, Kogan BA, Whitbeck C and Mannikarottu AS. Effect of maturation and age on estrogen induced functional hypertrophy of the female rabbit bladder. BJU International 99(3):674-679, March 2007.

Guven A, Lin WY, Leggett RE, Kogan BA, Levin RM and Mannikarottu A. Effect of aging on the response of biochemical markers in the rabbit subjected to short-term partial bladder obstruction. Molecular and Cellular Biochemistry 306(1–2):213-9, December 2007.

Lin WY, Mannikarottu A, Chichester P, Guven A, Johnson A, Neuman P, Juan YS, Schuler C, Kogan BA, and Levin RM. Changes in the smooth muscle of the corpora cavernosum related to reversal of partial outlet obstruction in rabbits. Journal of Andrology 29(2):164–71, Mar–April 2008.

Juan YS, Mannikarottu AS, Hydery T, Lin WY, Kogan BA, Whitbeck C, Leggett RE and Levin RM. Coenzyme Q10 protect against ischemia / reperfusion induced biochemical and functional changes in rabbit urinary bladder. Molecular and Cellular Biochemistry 311(1–2):73-80, April 2008.

Lin WY, Rehfuss A, Whitbeck C and Levin RM. Effect of co-enzyme Q10 and α-lipoic acid on the response of the rabbit urinary bladder to repetitive stimulation and in vitro ischemia. Urology 72(1):214–9, 2008.

Arnold Johnson Gertzberg N, Gurnani T, Neumann P, Forbes AK, Jean-Louis N and Johnson A. Tumor necrosis factor-± (TNF) causes barrier dysfunction mediated by tyrosine98 and tyrosine218 in β-actin.

American Journal of Physiology: Lung Cellular and Molecular Physiology 293(5):L1219–L29, August 2007.

Lin WY, Levin RM, Chichester P, Leggett R, Juan YS, Johnson A, Neumann P, Whitbeck C, Guven A, Kogan B and Mannikarottu A. Effects of L-arginine and L-NAME on chronic partial bladder outlet obstruction in rabbit. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 293(6):R2390–R9, October 2007.

Luciana B. Lopes Lopes LB, Furnish E, Komalavilas P, Seal BL, Panitch A, Bentley MV and Brophy CM. Enhanced skin penetration of P20 phosphopeptide using protein transduction domains. European Journal of Pharmaceutics and Biopharmaceutics 68(2):441-5, February 2008.

Komalavilas P, Penn RB, Flynn CR, Thresher J, Lopes LB, Furnish EJ, Guo M, Pallero MA, MurphyUllrich JE and Brophy CM. The small heat shockrelated protein, HSP20, is a cAMP-dependent protein kinase substrate that is involved in airway smooth muscle relaxation. American Journal of Physiology. Lung, Cellular and Molecular Physiology 294(1):L69–78, January 2008.

William R. Millington Yilmaz MS, Millington WR and Feleder C. The preoptic anterior hypothalamic area mediates initiation of the hypotensive response induced by lipopolysaccharide in male rats. Shock 29(2):232–237, 2008.

Millington WR. Sheep have the last word: Kappa and delta opioid receptors initiate hemorrhagic hypotension. Acta Physiologica 191:1, 2007.

Millington WR and Göktalay G. Neurochemical approaches to addiction treatment in Pain and Chemical Dependency (H. Smith H and S. Passik, eds.), New York: Oxford University Press, 2008.

Alexandre A. Steiner Steiner AA, Turek VF, Almeida MC, Burmeister JJ, Oliveira DL, Roberts JL, Bannon AW, Norman MH, Louis JC, Treanor JJ, Gavva NR and Romanovsky AA. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. The Journal of Neuroscience 27:7459–7468, 2007.

PrezRepVF

4/15/09

1:41 PM

Page 35

ACPHS 2008

Ootsuka Y, Blessing WW, Steiner AA and Romanovsky AA. Fever response to intravenous prostaglandin E2 is mediated by the brain but does not require afferent vagal signaling.

American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 294:R1294–R1303, 2008.

PROJECT: The spleen releases a splenic inhibitory factor that controls LPS fever SPONSOR: American Association of Colleges of Pharmacy TOTAL GRANT: $10,000 PROJECT PERIOD: January 2007–December 2010

// 35

Adwoa O. Nornoo PROJECT: Detection of penicillin G in blister packs of various drugs packaged by Heartland, Inc. SPONSOR: Office of the New York State Attorney General TOTAL GRANT: $2,200 PROJECT PERIOD: October 2007–January 2008

Jeffrey M. Voigt PROJECT: Splenic regulation of endotoxic fever Mandalaywala NV, Chang S, Snyder RS, Levendusky MC, Voigt JM and Dearborn Jr. RE. The tumor suppressor, vitamin D3 up-regulated protein 1 (VDUP1), functions downstream of REPO during Drosophila gliogenesis. Developmental Biology 315:489-504, 2008.

M. Sertac Yilmaz Yilmaz MS, Millington WR, and Feleder C. The preoptic anterior hypothalamic area mediates initiation of the hypotensive response induced by LPS in male rats. Shock 29(2):232–237, 2008.

Cansev M, Yilmaz MS, Ilcol YO, Hamurtekin E and Ulus IH. Cardiovascular effects of CDP-choline and its metabolites: involvement of peripheral autonomic nervous system. European Journal of Pharmacology 577:129–142, 2007.

Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E and Ulus IH. Intraperitoneal administration of CDPcholine and its cholinergic and pyrimidinergic metabolites induce hyperglycemia in rats: Involvement of the sympathoadrenal system.

Archives of Physiology and Biochemistry 113(4/5):186-201, 2007.

SPONSOR: Albany College of Pharmacy Intramural Grant

Alexandre A. Steiner

TOTAL GRANT: $5,000

PROJECT: Leptin is a pro-inflammatory cytokine: True or false?

PROJECT PERIOD: 2007–2008

SPONSOR: Scholarship of Discovery Grant, Albany College of Pharmacy

Arnold Johnson

TOTAL GRANT: $4,500

PROJECT: Biomarkers predicting the severity of obstruction-induced bladder dysfunction

PROJECT PERIOD: May 2008–June 2009

SPONSOR: Merit Review Award, Dept. of Veterans Affairs

Jeffrey M. Voigt

PRINCIPAL INVESTIGATOR: Robert M. Levin

PROJECT: Regulation of VDUP-1 expression in human tumor cells

TOTAL GRANT: $125,000 PROJECT PERIOD: April 2006–March 2010

SPONSOR: Albany College of Pharmacy Intramural Grant TOTAL GRANT: $5,000

PROJECT: A mechanism for TNF induced endothelial dysfunction SPONSOR: National Institute of Health, NHLBI TOTAL GRANT: $200,000

PROJECT PERIOD: July 2008–June 2009 PROJECT: Post-translational modification of VDUP-1 in human cells

PROJECT PERIOD: January 2005–January 2009

SPONSOR: Albany College of Pharmacy Intramural Grant

Robert M. Levin

TOTAL GRANT: $5,000

Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E and Ulus IH. Peripheral administration of CDP-choline and its cholinergic metabolites increases serum insulin: Peripheral muscarinic and nicotinic acetylcholine receptors are both involved in its action.

Neuroscience Letters 431(1):71–76, 2008.

PROJECT: Protection against ischemia and ischemia followed by reperfusion by Antrodia Camphorata

PROJECT PERIOD: July 2007–June 2008

Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E and Ulus IH. Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations.

Autonomic and Autacoid Pharmacology 28:41–58, 2008.

PROJECT PERIOD: 2007–2008

SPONSOR: Wellshine Pharmaceuticals TOTAL GRANT: $40,000 per year

PROJECT: Biomarkers predicting the severity of obstructive bladder dysfunction SPONSOR: Veteran’s Administration Medical Center

HaiAn Zheng PROJECT: Computer 3D molecular modeling and animation for pharmaceutics and pharmacy Education SPONSOR: Scholarship of Discovery and Educational Excellence, Albany College of Pharmacy TOTAL GRANT: $5,000 PROJECT PERIOD: May 2008–May 2009

TOTAL GRANT: $125,000 per year GRANTS

PROJECT PERIOD: 2006–2010

ABSTRACTS/PRESENTATIONS

Richard E. Dearborn Jr.

Luciana Lopes

Richard E. Dearborn

PROJECT: Mutagenic analysis of conserved amino acid function in the tumor suppressor Vitamin D3 Up-regulated Protein 1 (VDUP1)

TITLE: Use of campul-based microemulsions as topical delivery systems

Voigt JM, Basle J and Dearborn Jr. RE. Phosphorylation of VDUP-1 in human U-87 MG glioma cells. American Association for Cancer Research Annual Meeting, San Diego, Calif., April 2008.

SPONSOR: Albany College of Pharmacy Intramural Grant TOTAL GRANT: $5,000 PROJECT PERIOD: 2007–2008 Carlos Feleder PROJECT: The role of the spleen in the febrile response SPONSOR: National Institutes of Health TOTAL GRANT: $150,000 PROJECT PERIOD: October 2007–September 2010

SPONSOR: Scholarship of Discovery Grant, Albany College of Pharmacy TOTAL GRANT: $5,000 PROJECT PERIOD: May 2008–June 2009

Mandalaywala NV, Chang S, Snyder RG, Levendusky MC and Dearborn Jr. RE. Retinal axon-dependent regulation of vitamin D3 up-regulated protein 1 (VDUP1) tumor suppressor expression in the Drosophila optic lobe.

Neurobiology of Drosophila meeting, Cold Spring Harbor, N.Y., October 2007.

PrezRepVF

4/15/09

1:41 PM

Page 36

Mandalaywala NV, Chang S, Snyder RG, Levendusky MC and Dearborn Jr. RE. Retinal axon-dependent regulation of vitamin D3 up-regulated protein 1 (VDUP1) tumor suppressor expression in the Drosophila optic lobe.

Commission on Independent Colleges and Universities Undergraduate Research Exposition, Albany, N.Y., January 2008.

Carlos Feleder Marlow J, Yilmaz MS, Millington WR and Feleder C. Dose-dependent mechanisms mediate lipopolysaccharide hypotension in male rats.

Experimental Biology, San Diego, Calif., April 2008.

Yilmaz MS, Myer BS, Feleder C and Millington WR. Blockade of alpha-adrenergic receptors in the preoptic anterior hypothalamus prevents lipopolysaccharide evoked hypotension.

Experimental Biology, San Diego, Calif., April 2008.

Adwoa O. Nornoo Nornoo AO and Chikhale P. Microemulsion-based formulations of Paclitaxel: Anticancer activity against rat glioma cells and intestinal permeability.

2007 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, San Diego, Calif., November 2007.

Nornoo AO and Zheng H. Pharmacokinetics and NMR characterization of Paclitaxel microemulsions. 2007 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, San Diego, Calif., November 2007.

Alexandre A. Steiner Romanovsky AA, Steiner AA, Turek VF, Almeida MC, Burmeister JJ, Oliveira DL, Roberts JL, Bannon AW, Norman MH, Louis J-C, Treanor JJS and Gavva NR. Non-thermal activation of TRPV1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. 37th Annual Meeting of the Society for Neuroscience, San Diego, Calif., 2007.

Robert M. Levin Levin RM. Update on studies on obstructive bladder dysfunction. Lund University, Lund, Sweden, September 2007.

Levin RM. Ischemic etiology of obstructive bladder dysfunction: Effect of Antrodia Camphorata.

Antrodia Comphorata Symposium, Taipei, Taiwan, March 2008.

Jeffrey M. Voigt Basle J and Voigt JM. Phosphorylation of VDUP-1 in human U87-MG glioma cells. American Association for Cancer Research, San Diego., Calif., April 2008.

M. Sertac Yilmaz Levin RM. Ischemic etiologies of male and female urological dysfunctions. Veteran’s General Hospital, Taipei, Taiwan, March 2008.

Levin RM. Beneficial effects of Antrodia Comphorata. Taichung General Hospital, Taichung, Taiwan, March 2008.

Levin RM. Anti-ischemic effects of Antrodia Comphorata. Taipei General Hospital, Taipei, Taiwan, March 2008.

Luciana B. Lopes Hosmer J, Reed R, Nornoo AO, Lopes LB. Influence of microemulsion composition on the skin penetration and percutaneous delivery of Progesterone. 11th Annual American Association of Pharmaceutical Scientists Northeast Regional Discussion Group, Rocky Hill, Conn., April 2008.

Komalavilas P, Lopes LB, Flynn CR, Smoke C, Seal B, Panitch A and Brophy CM. Reduction of heat chock protein 27 phosphorylation inhibits the development of intimal hyperplasia. Experimental Biology 2008, San Diego, Calif., April 2008.

William R. Millington Yilmaz MS, Myer BS, Feleder C and Millington WR. Blockade of α-adrenergic receptors in the preoptic area/anterior hypothalamus prevents lipopolysaccharide evoked hypotension.

Experimental Biology 2008, San Diego, Calif., April 2008.

Marlow J, Yilmaz MS, Millington WR and Feleder C. Dose-dependent mechanisms mediate lipopolysaccharide (LPS) hypotension in male rats. Experimental Biology 2008, San Diego, Calif., April 2008.

Yilmaz MS, Myer BS, Feleder C and Millington WR. Blockade of α-adrenergic receptors in the preoptic area/anterior hypothalamus prevents lipopolysaccharide evoked hypotension.

Experimental Biology 2008, San Diego, Calif., April 2008.

Marlow J, Yilmaz MS, Millington WR and Feleder C. A neural route signals the brain in endotoxic hypotension: Role of the vagus nerve and αadrenoceptors in the preoptic anterior hypothalamic area. Experimental Biology 2008, San Diego, Calif., April 2008.

HaiAn Zheng Nornoo AO and Zheng H. Pharmacokinetics and NMR characterization of paclitaxol microemulsion.

American Association of Pharmaceutical Scientists Annual Meeting, San Diego, Calif., November 2007.

PrezRepVF

4/15/09

1:41 PM

Page 37

ACPHS 2008

// 37

Arts and Sciences PUBLICATIONS James Anderson Anderson J and Applegate E. The psychological robot: A new tool for learning. International Journal of Teaching and Learning in Higher Education 19(3):305-314, 2007.

Kenneth J. Blume Blume KJ. The talented tenth and American foreign policy: African-Americans in the U.S. Diplomatic Corps, 1865-1914. The Mind’s Eye: A Liberal Arts Journal (Massachusetts College of Liberal Arts), 2007.

Blume KJ. Entries on Rush-Bagot Treaty, AngloAmerican Treaty, Adams-Onis Treaty, WebsterAshburton Treaty, Oregon Treaty, Treaty of Guadalupe Hidalgo, Alaska Purchase, Burlingame Treaty, Hay-Herran Treaty and Hay-Bunau-Varilla Treaty in Encyclopedia of the Age of Imperialism: 1800–1914 (Carl Cavanagh Hodge, ed.), Westport, Conn.:Greenwood Press, 2007.

Blume KJ. Entries on Alexander Clark, William Henry Harrison Heard, William Frank Powell and John E. W. Thompson in African American National Biography (Henry Louis Gates and Evelyn Higginbottom, eds.), New York: Oxford University Press, 2008.

Blume KJ. Review of Angus Curry’s The Officers of the CSS Shenandoah. H-Maritime, May 2007.

Hass MA, Siflinger-Birnboim A and Levin RM. Hydroxynonenal in obstructed urinary bladder disease. Federation of American Societies for Experimental Biology Journal 21(6):lb31, April 2007.

Blume KJ. Who needs to know about the Schlieffen Plan? Focusing on the ’big picture’ and World War I. World History Association Annual Conference, University of Wisconsin, Milwaukee, Wisc. July 2007.

Kevin M. Hickey Hickey KM and Karatsolis A. A Rocky-HorrorPicture Show pedagogy: Tablet PC use in Humanities and Communication student-centered classrooms. University College of the Fraser Valley Research Review 1(3): 26-37.

Hickey KM. Entries on Exploration and Explorers, Africa; Ralph Ellison; Morant Bay Rebellion; Race, History of; and Soukous in Africa and the Americas: Culture, Politics, and History (3 volumes, Richard M. Juang and Noelle Morrissette, eds.). Santa Barbara: ABC-CLIO Press, 2008.

Marion Jacobson Jacobson M. Searching for rockordion: The changing image of the accordion in America in the Twentieth Century. American Music 3: 123-159.

Margaret Carroll Carroll M. Conflict, coexistence and community: Creatures of the Earth by John McGahern.

American Conference of Irish Studies National Conference, St. Ambrose University, Davenport, Iowa, April 2008.

Ray Chandrasekara Chandrasekara R. Borders, boundaries, bodies: Caliban re-membered. International Humanities Conference, Paris, France, July 2007.

Chandrasekara R. Water and state security.

International Social Science Conference, Grenada, Spain, July 2007.

J. Daniel d’Oney Andreas Karatsolis Hickey KM and Karatsolis A. A Rocky-HorrorPicture Show pedagogy: Tablet PC use in Humanities and Communication student-centered classrooms. University College of the Fraser Valley Research Review 1(3): 26–37.

Blume KJ. Review of Eric J. Graham and Clyde Built’s Blockade Runners, Cruisers and Armoured Rams of the American Civil War. The Northern Marine/Le Marin Du Nord, July 2007.

Karatsolis A. Revamping the honor code in a professional curriculum. Integrity Matters: Center for Academic Integrity, 2008.

Margaret Lasch Carroll

Karatsolis A. Tablets as writing canvases and construction sites in The Impact of Tablet PCs and Pen-based Technology on Education: Vignettes, Evaluations, and Future Directions (Berque, et al, eds.), Purdue University Press, September 2007.

Carroll ML. Prodigals’ dreams: John McGahern’s That They May Face the Rising Sun. Estudios Irlandeses 3:42-53, 2008.

Kenneth J. Blume

D’Oney JD. Have You Heard: The Past in First Person from the T. Harry Williams Center for Oral History (researched and curated the section on the United Houma Nation for museum exhibit).

Hill Memorial Library, Baton Rouge, October 22, 2007–March 30, 2008.

Ellen B. Duffy Duffy EB and Harton JA. Anthrax lethal toxins induces caspase-independent apoptosis in human and murine macrophage cell lines. American Society for Microbiology 108th General Meeting, Boston, Mass., June 2008.

Martha A. Hass Michael Pittman

Ray Chandrasekara Chandrasekara R. Borders, boundaries, bodies: Caliban re-membered. International Journal of the Humanities 5(10):189-98, 2007.

Chandrasekara R and Polimeni JM. Water and national security. International Journal of Interdisciplinary Social Sciences 2(6):11-20, 2008.

Chandrasekara R. Entries on When the Rainbow Goddess Wept and Ninotchka Rosca in Encyclopedia of American Ethnic Literature/Asian American volume (Seiwong Oh, ed.), Facts on File, 2008.

J. Daniel d’Oney d’Oney JD. Watered by tempests: Hurricanes in the cultural fabric of the United Houma Nation.

American Indian Culture and Research Journal 32(2):11-26, 2008. d’Oney JD. River queens, sternwheelers and canyon cats. Pacific Northwest Quarterly.

99(1):40-42, Winter 2007/2008.

Martha A. Hass Siflinger-Birnboim A, Levin RM and Hass MA. Partial outlet obstruction of the rabbit urinary bladder induces selective protein oxidation.

Neurourology and Urodynamics 26:1-7, 2007.

Pittman M. Soul making in all and everything.

Proceedings of the 12th International Humanities Conference: All and Everything International Humanities Conference 2007.

Hass MA, Siflinger-Birnboim A and Levin RM. Hydroxynonenal in obstructed urinary bladder disease. Federation of American Societies for Experimental Biology/ Annual Experimental Biology meeting, Washington, D.C., April 2007.

Laura Rogers

Kevin M. Hickey

Rogers L. Finding our way from within: Critical pedagogy in a prison writing class. Open Words 2(1): 22–48, Spring 2008.

Hickey KM. Diverting “les flots souterrains” to cultivate the cosmopolitans in Veronique Tadjo’s L’Ombre d’Imana (The Shadow of Imana). 34th Annual Conference of the African Literature Association, Macomb, Ill., April 2008.

Sandra Winn Winn S. George Elder’s story “Passion and Sparks.” The Authentic Dissertation: Alternative Ways of Knowing, Research and Representation (Four Arrows AKA Don Trent Jacobs). New York: Routledge Press. pp 175-184.

ABSTRACTS/PRESENTATIONS Patricia Baia Baia P. CDETG: Active learning: In or outside the classroom. Albany College of Pharmacy, Albany, N.Y., June 2008.

Marion Jacobson Jacobson M. Italian dance hall culture: The accordion as a symbol of pluralism and ethnicity.

Italians in the Americas Conference, New York, N.Y., April 2008.

Andreas Karatsolis Karatsolis A. Designing effective websites: Innovation in project-based learning. American Association of Colleges of Pharmacy Annual Meeting, Orlando, Fla., July 2007.

PrezRepVF

4/15/09

1:41 PM

Page 38

Erika A. Muse

Martha Hass

Muse EA. From theory to practice: Building competencies in intercultural encounters in Asian America. Association for Asian American Studies, Chicago, Ill., April 2008.

PROJECT: Ischemic etiology of obstructive bladder dysfunction

Michael Pittman

PRINCIPAL INVESTIGATOR: Robert Levin

Pittman M. Gurdjieff: Religion and its discontents.

American Society for Esoteric Studies Conference in Charleston, S.C., May-June, 2008.

Pittman M. Gurdjieff’s view of education in All and Everything. Armenia-Gurdjieff Conference, Yerevan, Armenia, July 2007.

Laura Rogers Rogers L. Diving Into prison teaching: Mina Shaughessy, teacher development and the realities of prison teaching. Conference on College Composition and Communication, New Orleans, La., April 2008.

Elisabeth A. Vines Vines E. Pictures of potatory pleasures: Nineteenth century France. Fourth International Conference on Drugs and Alcohol in History, Guelph, Ontario, Canada, August 2008.

Sandra Winn Winn S. Our strategy for achieving tolerance among our campus community. National Association for Multicultural Education meeting, Baltimore, Md., October-November 2007.

Winn S. Implications for moral education practices from the field. Association for Moral Education, New York, N.Y., November 2007.

SPONSOR: National Institutes of Health—National Institute of Diabetes, Digestive and Kidney Disease TOTAL GRANT: $1,154,280 PROJECT PERIOD: 2004–2008.

PROJECT: The role of the spleen in the febrile response SPONSOR: National Institutes of Health— Neuroendocrinology, Neuroimmunology and Behavior PRINCIPAL INVESTIGATOR: Carlos Feleder TOTAL GRANT: $194,553 PROJECT PERIOD: 2008–2010.

Michael Pittman PROJECT: Armenia-Gurdjieff Conference (organizer) SPONSOR: Indications Press TOTAL GRANT: $600 PROJECT PERIOD: July 2007

Health Sciences ABSTRACTS/PRESENTATIONS Indra Balachandran Balachandran I and Walker J. Curriculum mapping. 55th Annual Meeting of the American Society of Cytopathology, Houston, Tex., November 2007.

EXHIBITIONS Elisabeth E. Vines Vines EA. Oil works (21 recent paintings).

Bethlehem Public Library, Delmar, N.Y., January 2008.

Balachandran I. Small blue cell tumors of childhood: Case study approach. Teleconference Network of Texas series, University of Texas Health Science Center, San Antonio, Tex., March 2008.

Vines EA. New Mustache. Third Annual Members’ Show, Albany Center Gallery, Albany, N.Y., December 2007–January 2008.

Vines EA. Window Series (11 oil paintings). Café at the Honest Weight Food Co-op, Albany, N.Y., September 2007.

GRANTS Kenneth J. Blume PROJECT: Sable Diplomats: African Americans in the U.S. Diplomatic Corps, 1865-1914 SPONSOR: Albany College of Pharmacy TOTAL GRANT: $3,240 PROJECT PERIOD: 2007–2008

Bolded names indicate ACPHS faculty collaborators

PrezRepVF

4/15/09

1:41 PM

Page 39

ACPHS 2008

// 39

Department of Pharmaceutical Sciences—Student Publications BSPS STUDENTS

PUBLICATIONS Juan Y-S, Mannikarottu A, Hydery T, Lin W-Y, Kogan BA, Whitbeck C, Leggett RE, Levin RM. Coenzyme Q10 protect against ischemia / reperfusion induced biochemical and functional changes in rabbit urinary bladder. Molecular and Cellular Biochemistry 311:73-80, 2008.

Juan Y-S, Levin RM, Hydery T, Chuang SM, Li S, Leggett RE, Huang CH, Mannikarottu A. Protective effect of coenzyme Q10 plus lipoic acid against obstructive bladder dysfunctions in the rabbit. Journal of Urology (In Press).

Lin W-Y, Rehfuss A, Whitbeck C, Juan W-S, Chichester, Mannikarottu A, Levin RM. Effect of Letrozole on female rabbit Urinary bladder function. BJU International 100:1391-1395, 2007.

Lin W-Y, Rehfuss A, Whitbeck C, Levin RM. Effect of coenzyme Q10 and α-lipoic acid on the response of the rabbit urinary bladder to repetitive stimulation and in vitro ischemia. Urology 72(1):214-9, July 2008 [Epub, February 2008].

Lin W-Y, Radu F, Schuler C, Leggett RE, Mannikarottu A, Levin RM. Effect of ovariectomy and estrogen therapy on the free fatty acid content, endogenous lipase activity, and phospholipid content of the rabbit urinary bladder. BJU International 102(7):885-9, September 2008 [EPub, May 2008] Mandalaywala NV, Chang S, Snyder RG, Levendusky MC, Voigt JM, Dearborn Jr RE. The tumor suppressor, vitamin D3 up-regulated protein 1 (VDUP1), functions downstream of REPO during Drosophila gliogenesis. Developmental Biology 315:489-504, 2008.

Yilmaz, MS, Göktalay G, Myer BS, Millington WR, Cutrera R, Feleder C. Lipopolysaccharide-induced hypotension is mediated by a neural pathway involving the vagus nerve, the nucleus tractus solitarius and alpha-adrenergic receptor in the preoptic anterior hypothalamic area. Journal of Neuroimmunology 203(1):39-49, October 2008.

ABSTRACTS Juan Y-S, Mannikarottu A, Hydery T, Kogan BA, Schuler C, Leggett RE, Levin RM, Coenzyme Q10 and alpha lipoic acid as a treatment for partial bladder outlet obstruction induced bladder dysfunction. American Urological Society Meeting, Orlando, Fla., May 2008.

Radu F, Lin W-Y, Chichester P, Leggett RE, Mannikarottu A, Levin RM. Effect of ovariectomy and estrogen administration on free fatty acid, and phospholipid concentrations of the rabbit urinary bladder muscle and mucosa. American Urological Society Meeting, Orlando, Fla., May 2008.

Nornoo AO, Owusu-Obeng A, Myer BS, Nguyen H, Reed R. Effect of oral microemulsions (MEs) on the permeability (peff) of paclitaxel (PAC) across rat GIT and caco-2 cell monolayers. American Association for Cancer Research Annual Meeting, Los Angeles, Calif., April 2007.

PHARM.D. STUDENTS

PUBLICATIONS Mandalaywala NV, Chang S, Snyder RG, Levendusky MC, Voigt JM, Dearborn Jr RE. The tumor suppressor, vitamin D3 up-regulated protein 1 (VDUP1), functions downstream of REPO during Drosophila gliogenesis. Developmental Biology 315:489-504, 2008.

Nornoo A, Zheng H, Lopes LB, Reed R, et al.

Oral microemulsions of paclitaxel in situ and phamacokinetic studies. European Journal of Pharmaceutics and Biopharmaceutics 71(2):310–7, February 2009.

ABSTRACTS Wong P, Blustein L, Policastro C, Zheng H. Pharmaceutics Online-Homework: Calculation Practice and Evaluation in Large-Class. AACP Annual Conference, 2008.

Mandalaywala NV, Chang S, Snyder RG, Levendusky MC, Dearborn Jr, RE. Retinal axondependent regulation of vitamin D3 up-regulated protein 1 (VDUP1) tumor suppressor expression in the Drosophila optic lobe. Cold Spring Harbor Neurobiology of Drosophila Meeting, Cold Spring Harbor, NY, October 2007.

Hosmer J, Reed R, Nornoo N, Lopes LB. Influence of microemulsion composition on the skin penetration and percutaneous delivery of progesterone. 11th Annual AAPS Northeast Regional Discussion Group, Rocky Hill, Conn., April 2008.

Mandalaywala NV, Chang S, Snyder RG, Levendusky MC, Dearborn Jr, RE. Retinal axondependent regulation of vitamin D3 up-regulated protein 1 (VDUP1) tumor suppressor expression in the Drosophila optic lobe. CICU Undergraduate Research Exposition, Albany, NY, January 2008.

Nornoo AO, Owusu-Obeng A, Myer BS, Nguyen H, Reed R. Effect of oral microemulsions (MEs) on the permeability (peff) of paclitaxel (PAC) across rat GIT and caco-2 cell monolayers. American Association for Cancer Research Annual Meeting, Los Angeles, Calif., April 2007.

Voigt JM, Basle J, Dearborn Jr, RE. Phosphorylation of VDUP-1 in human U-87 MG glioma cells. AACR Annual Meeting, San Diego, Calif., April 2008.

Mandalaywala NV, Chang S, Snyder RG, Levendusky MC, Dearborn Jr, RE. Retinal axondependent regulation of vitamin D3 up-regulated protein 1 (VDUP1) tumor suppressor expression in the Drosophila optic lobe. Cold Spring Harbor Neurobiology of Drosophila Meeting, Cold Spring Harbor, NY, October 2007.

Marlow J, Yilmaz MS, Millington W, Feleder C. Dose-dependent mechanisms mediate lipopolysaccharide hypotension in male rats.

Experimental Biology 2008, San Diego, Calif., April 2008.

Yilmaz MS, Myer BS, Feleder C, Millington W. Blockade of alpha-adrenergic receptors in the preoptic anterior hypothalamus prevents lipopolysaccharide evoked hypotension.

Experimental Biology 2008, San Diego, Calif., April 2008.

Mandalaywala NV, Chang S, Snyder RG, Levendusky MC, Dearborn Jr, RE. Retinal axondependent regulation of vitamin D3 up-regulated protein 1 (VDUP1) tumor suppressor expression in the Drosophila optic lobe. CICU Undergraduate Research Exposition, Albany, NY, January 2008.

Bolded names indicate ACPHS students

PrezRepVF

4/15/09

1:41 PM

Page 40

SUPPORT STUDENT SCHOLARSHIP AND FA C U LT Y D E V E LO P M E N T

Academic Excellence + Research Opportunities

ENABLE STUDENT A N D FA C U LT Y RESEARCH ENSURE S TAT E - O F -T H E - A R T RESEARCH LABS AND PROGRESSIVE T E C H N O LO G I E S

The possibilities are endless with your gift.

Make a difference to the ACPHS community.

Please make checks payable to Albany College of Pharmacy and Health Sciences and mail to Office of Institutional Advancement Albany College of Pharmacy and Health Sciences 106 New Scotland Ave. Albany, New York 12208

Go green and make your gift online www.acphs.edu, click on Online Giving.

ACPHS accepts both MasterCard and Visa Telephone 518.694.7253 888.203.8010 Toll Free

CoverF

4/15/09

1:43 PM

Page 4

A L B A N Y C O L L E G E O F P H A R M A C Y A N D H E A LT H S C I E N C E S

James J. Gozzo, Ph.D.

Mehdi Boroujerdi, Ph.D., Pharm.D.

PRESIDENT

DEAN

Board of Trustees OFFICERS

TERM TRUSTEES

CHAIRMAN EMERITUS

Kandyce J. Daley ’74

Stephen C. Ainlay James E. Bollinger ’58 Robert S. Busch Herbert Chorbajian J. Gordon Dailey ’57 Richard H. Daffner ’63 Francis J. DiLascia ’54 Melvin Friedland ’58 Geno J. Germano Jr. ’83 Zachary I. Hanan ’63 David M. Kile ’74 Jeannette S. Lamb ’57 Joseph Lapetina Thomas O. Maggs Robert F. McGaugh ’57 Christopher Mitiguy Fouad Morkos Richard G. Robison ’52

Alfred J. Collins Jr. ’53

CHAIR

Hugh A. Johnson VICE CHAIR

Christopher Del Vecchio ’88 TREASURER

Bridget-ann Hart ’80 SECRETARY

TRUSTEES EMERITUS Michael Bette Kenneth M. Nirenberg

Research OFFICE OF GRANTS ADMINISTRATION Sunita Chowfin GRANTS ADMINISTRATOR 518.694.7144 sunita.chowfin@acphs.edu

PHARMACEUTICAL RESEARCH INSTITUTE Shaker A. Mousa, Ph.D. EXECUTIVE VICE PRESIDENT AND CHAIRMAN 518.694.7397 shaker.mousa@acphs.edu

Office of Institutional Advancement Vicki A. DiLorenzo

Gil Chorbajian

Deborah S. Reutter

VICE PRESIDENT OF INSTITUTIONAL ADVANCEMENT 518.694.7331 vicki.dilorenzo@acphs.edu

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS 518.694.7394 gil.chorbajian@acphs.edu

COORDINATOR OF INSTITUTIONAL ADVANCEMENT 518.694.7220 debbie.reutter@acphs.edu

David Zdunczyk

Christine A. Shields

ASSISTANT VICE PRESIDENT OF INSTITUTIONAL ADVANCEMENT 518.694.7251 david.zdunczyk@acphs.edu

Deanna Ennello-Butler

Donna Beebe

Candace Madden

DIRECTOR OF MAJOR GIFTS 518.694.7125 donna.beebe@acphs.edu

SYSTEMS ADMINISTRATOR 518.694.7156 candace.madden@acphs.edu

Michael J. Buckley

Patrick Rathbun

MAJOR GIFTS OFFICER 518.694.7126 michael.buckley@acphs.edu

ASSISTANT DIRECTOR OF MARKETING AND COMMUNICATIONS 518.694.7131 patrick.rathbun@acphs.edu

DIRECTOR OF ADVANCEMENT RESEARCH 518.694.7305 deanna.ennello-butler@acphs.edu

DIRECTOR OF COLLEGE PUBLICATIONS 518.694.7393 alumni@acphs.edu

Christina Spinelli Sanvidge COORDINATOR OF DONOR RELATIONS AND STEWARDSHIP COORDINATOR OF ACPHS ACADEMY 518.694.7127 christina.spinelli@acphs.edu

CoverF

4/15/09

1:43 PM

Page 1

NON-PROFIT ORG US POSTAGE

Paid ALBANY NY PERMIT NO. 349